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ABSTRACT 
 
The cancer epidemic continues to afflict millions of humans world-wide each year and 
despite a renewed hope with the development of new and improved forms of therapy, a cure for 
cancer remains an elusive goal. This is partly related to the rise of resilient forms of tumors that 
have evolved with resistance towards conventional chemotherapy and radiation treatments. 
Moreover, these non-specific therapeutic regimens are highly toxic, leading to severe 
immunosuppressive effects which poisons the body and compromises the road towards 
remission. In an effort to mitigate these limitations, cancer-targeting approaches are currently 
experiencing a renaissance in the translation of new medicines from pre-clinical to bedside use. 
Notably, gene therapy has recently gained widespread traction in cancer research in the advent of 
the first RNA interference (RNAi) application in humans. RNAi solicits the use of a double-
stranded RNA substrate, aptly named short-interfering RNA (siRNA), which binds to and 
triggers the degradation of a targeted complementary mRNA strand within the catalytic site of a 
protein complex named, the RNA-Induced Silencing Complex (RISC). In this manner, malignant 
mRNA expression is silenced, thereby inhibiting the translation of proteins that can lead to the 
production of pathological disorders such as cancer.  In spite of their utility, several challenges 
still remain towards the development of a fruitful cancer-targeting gene therapy approach. For 
example, native siRNAs are plagued by poor pharmacokinetic properties which limit their 
therapeutic index and utility in clinical applications.     
 In this thesis, a new class of siRNA motifs is presented to increase substrate efficacy in 
the RNAi application. Our biological target is a member of the heat shock family of chaperone 
proteins, the Glucose Regulated Protein of 78 kilodaltons (GRP78) which signals tumor 
initiation, proliferation and resistance towards chemotherapy. Moreover, GRP78 is 
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overexpressed and cell surface localized on a wide range of resilient tumor types but not on 
healthy cells, making it a viable bio-marker for the development of the proposed cancer-targeting 
gene therapy approach. 
 Significantly, an efficient solid-phase synthesis method is described in Chapter 2 for the 
production of linear, V-shape, Y-branch and  hyperbranch GRP78-silencing siRNAs. The 
novel V-shape, Y-branch and  hyperbranch motifs were then studied by CD spectroscopy and 
thermal denaturation experiments (Chapter 3). CD spectroscopy was used to characterize the 
requisite A-type double-stranded RNA helix for RNAi application; whereas thermal denaturation 
experiments were used to validate siRNA hybrid stabilities. With stable siRNA hybrids in hand, 
their biological activity was next assessed in HepG2 hepatoblastoma cells, which constitutes a 
morbid form of pediatric liver cancer and a valid tumor model for studying our GRP78-targeting 
strategy. In Chapter 4 of this thesis, the GRP78 silencing activity of the putative branch and 
hyperbranch siRNAs is discussed and related to its underlying mechanisms for inducing 
apoptosis in cancer. Towards the development of an effective cancer-targeting gene therapy 
approach, Chapter 5 highlights preliminary results that showcase the utility of a cancer-targeting 
peptide (CTP) to condense and deliver siRNA within cancer cells for therapeutic treatment. The 
latter forms the basis of our cancer-targeting gene therapy approach. This thesis represents an 
important contribution towards this ultimate goal, in an effort to selectively eradicate some of the 
most lethal forms of cancer.      
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CHAPTER 1. DISCOVERY AND ANTI-CANCER APPLICATIONS OF 
SHORT-INTERFERING RNA (siRNA)  
1.1 DISCOVERY OF siRNA AND ITS ROLE IN THE RNA INTERFERENCE (RNAI) 
PATHWAY 
 
 RNA interference (RNAi) occurs naturally in animal and plant cells for regulating gene 
expression into functional proteins for normal cell structure and activity.
1
 A crucial component to 
the RNAi application is the gene-silencing activity of short (18-21 base-pairs) double-stranded 
RNA (dsRNA) also known as short-interfering RNA (siRNA). siRNAs are produced naturally 
from the enzymatic processing of lengthy dsRNA sequences. Once formed, siRNAs are recruited 
into a protein complex referred to as the RNA-Induced Silencing Complex (RISC). A subunit of 
this protein complex (Ago2) catalyzes the hydrolytic degradation of a single siRNA strand, 
referred to as the sense-strand RNA (ssRNA). The remaining antisense-strand RNA (asRNA) 
functions as a template for targeting and binding to a complementary messenger RNA (mRNA) 
sequence for down-regulating its gene expression into protein form. In this mechanism, the 
asRNA:mRNA hybrid bound within the active site of RISC inhibits ribosome binding and the 
assembly of the translational machinery for protein synthesis. Moreover, RISC catalyzes the 
degradation of the mRNA strand facilitating the turnover of additional mRNA for potent gene 
silencing effects (Figure 1.1).  
2 
 
 
Figure 1.1. RNAi mechanism for silencing mRNA expression.
1 
 
The discovery of the RNAi mechanism was accidental, initially dating back to 1990 with 
the work of Jorgenson and co-workers in which they attempted to make a ‘super purple’ 
petunia.
2
 Following insertion of an extra copy of a ‘purple’ gene targeting the production of 
chalcone synthase, the enzyme responsible for the production of the purple pigment anthocyanin 
in petunias, only white petunias were discovered. Albeit the mechanism responsible for down-
regulating gene expression remained unclear, this discovery proved to be the first application of 
RNAi. It was not until 1998, when the seminal works of Fire and Mello produced a full 
understanding of the RNAi mechanism in the nematode Caenorhabditis Elegans.
3
 For their 
contributions, Fire and Mello were awarded the Nobel Prize in physiology or medicine in 2006.  
Shortly after its discovery and characterization, RNAi research has evolved and demonstrated 
many fruitful applications of synthetic siRNAs for treating human diseases associated with the 
3 
 
expression of malignant genes (e.g. metabolic disorders, cancer, gene mutations and deletions 
etc.).
1
  
1.2 RNAi IN CANCER 
In relation to cancer, a number of siRNAs have demonstrated potent silencing of 
oncogene targets and anti-cancer effects in metastatic cell lines and in tumor-bearing animal 
models (Table 1.1).
4
  
These include siRNAs targeting the oncogenesis pathways
5-14
, such as the Ras, Raf, c-
Myc and HIF genes that are overexpressed in a variety of tumor tissues, including those 
associated with ovarian, melanoma and the pancreas. These oncogenes harbor cancer initiation, 
proliferation, and angiogenesis that led to the generation of metastatic forms of tumors that were 
found to be resilient to chemical and radiation treatments. In these cases, siRNA administration 
proved successful in halting the progression of these cancer types while resulting in significant 
tumor shrinkage.  
The siRNAs targeting the anti-apoptotic factors aim to silence the causative genes in 
cancer that are responsible for evading the cell death pathways.
15-18
 The anti-apoptotic oncogenes 
play a pivotal role in cancer cell replication without restriction, which is another hallmark of the 
disease.
19
 siRNAs that may effectively silence the anti-apoptotic genes may lead to the activation 
of the cell death effectors (e.g. Caspase 3 and 7) which stimulate the signaling pathways that are 
associated with the cell death response (apoptosis).
20
 For example, B-cell lymphoma 2 (Bcl-2) is 
an anti-apoptotic factor that is over expressed in many tumor tissues such as those belonging to 
the prostate and has been validated as a therapeutic target for pre-clinical RNAi application.
15
 
Other anti-apoptotic oncogene targets include: Survivin
16,17
, the Fas-associated death domain-
like interleukin-1β-converting enzyme-like inhibitory protein (FLIP) and X-chromosome linked 
IA (XIAP)
18 
have all demonstrated favorable responses to siRNA treatment in cancer cell lines 
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and tumor-bearing animal models. Moreover, down-regulation of Bcl-2 and XIAP with siRNA 
treatment sensitized drug-resistant breast cancer cells to Etoposide and Doxorubicin anti-cancer 
drugs, illustrating the potential for developing combination strategies involving oncogene and 
chemotherapeutics for more potent anti-cancer effects.
18
  
The cell cycle regulators including the retinoblastoma tumor suppressor (Rb) and p53 
pathways have been found to play a critical role in disrupting cellular senescence in cancer, the 
ability for cells to divide finite times before soliciting the cell death cascade.
21
 Thus, siRNAs 
have been applied for silencing the expression of tumor suppressors and regaining cellular 
senescence. These effects have been demonstrated following siRNA treatment of Cyclin B1 and 
E6 tumor suppressor genes in cervical and prostate cancers, respectively.
22-24
 Moreover, potent 
anti-cancer effects have also been demonstrated by silencing the human telomerase activity 
which has also been found to play a pivotal role in maintaining cellular senescence.
25-26
  
The interaction between the developing cancer cell and the host environment (known as 
the tumor microenvironment) facilitates angiogenesis (formation of new blood cells) and tumor 
invasion (metastatic growth), another hallmark of cancer.
19
 These tumor promoting oncogenes 
are associated with the vascular endothelial growth factor (VEGF) and chemokine receptor 
(CXCR4) among others, and have each been targeted with siRNAs for induction of leukemia, 
prostate and breast cancer cell death.
27-31
  
Cancer drug resistance has limited the applications of chemotherapeutic agents in the 
treatment of cancer.
32
 Cancer drug resistance has been partly associated with expression of the 
multidrug resistance gene (MDR1). For example, P-glycoprotein (P-gp) functions as a membrane 
bound efflux protein, which binds to intracellular drugs and pumps them out of the cell for 
limited to inconsequential therapeutic effect.
33
 Targeting MDR1 with siRNA has sensitized 
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cancer cells to chemotherapeutics such as Doxorubicin and Taxol, by eliminating their drug 
resistance and inducing cancer cell death.
34-35
  
Table 1.1. RNAi in pre-clinical cancer therapy
4
 
Pathway Oncogenes Cancer types 
Oncogenesis  Ras Ovarian5 
Mealnoma
6
 
 Raf Melanoma
7
 
Prostrate
8
 
Breast
9
 
 BCR-ABL Chronic  myelogenous leukemia (CML)
10
 
 Beta catenin Colon
11
 
 c-Myc Breast carcinoma
12
 
 HIF-1 Cervical and colon
13
 
Breast and glioma
14
 
Apoptosis Bcl-2 Prostate
15
 
 Survivin Esophageal
16
 
Glioma
17
 
 Bcl-2 and XIAP Breast
18
 
Cell cycle regulators E2F4 Prostrate
22
 
 E6, E7 Cervical
23
 
 Cyclin B1 Cervical
24
 
Cell senescence hTER Colon and melanoma
25
 
 hTERT Bladder
26
 
Tumor-host interactions VEGF Ewing’s sarcoma27 
Leukemia
28
 
 CD31 Prostrate
29
 
 RhoA/RhoC Breast
30
 
 CXCR4 Breast
31
 
Chemotherapy 
resistance 
MDR1 Pancreatic and gastric carcinoma
34
 
Uterine sarcoma
35
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In light of the flourishing pre-clinical data, a series of clinical trials have been issued 
(Table 1.2).
36
 This has led to the first human clinical trials for the application of siRNAs in the 
treatment of liver cancers.
37
 In spite of its unlimited potential, few siRNAs have effectively 
translated from the pre-clinical to clinical applications raising the unmet need to develop more 
potent and efficacious constructs.  
 
Table 1.2. siRNA candidates in oncology clinical trial as of 2012 adapted from Uchino et al
36
 
and ClinicalTrials.gov. 
 
ClinicalTrials.gov 
identiﬁer  
Drug  Route  Delivery  Disease  Target  Phase  States  Company  
NCT00499590  Bevasir
anib  
IVT  Naked 
siRNA  
Wet AMD  VEGF  III  Termi
nated  
Opko 
Health  
NCT00363714, 
NCT00395057  
AGN21
1745/ 
Sirna – 
027  
IVT  Naked 
siRNA  
AMD  VEGF-R1  II  Termi
nated  
Allergan/ 
Sirna  
NCT01065935, 
NCT00658086  
ALN-
RSV01  
Nebuliz
ation  
Naked 
siRNA  
RSV infection 
after lung 
transplantation  
RSV 
Nucleocaps
id  
II  Compl
eted  
Alnylam  
NCT00306904  Bevasir
anib  
IVT  Naked 
siRNA  
DME  VEGF  II  Compl
eted  
Opko 
Health, Inc.  
NCT01445899  PF-
045236
55  
IVT  Naked 
siRNA  
DME  RTP801  II  Recrui
ting  
Quark 
Pharma  
NCT01200420  miravirs
en  
SC  Naked 
LNA  
HCV  miR-122  II  Compl
eted  
Santaris 
Pharma  
NCT01551745 
NCT01505166  
FANG 
vaccine  
Ex 
vivo, 
Intrader
mal  
Electropor
ation  
Ovarian cancer, 
colon cancer  
Bi-shRNA-
Furin and 
GM-CSF  
II, II  Recrui
ting, 
Recrui
ting  
Gradalis, 
Inc.  
NCT00802347  I5NP  IV  Naked 
siRNA  
DGF in kidney 
transplantation  
P53  I/II  Recrui
ting  
Quark 
Pharma  
NCT01227291  SYL040
012  
Ophthal
mic 
drops  
Naked 
siRNA in 
ophthalmi
c drops  
Glaucoma and 
ocular 
hypertension  
Adrenergic 
receptor 
beta-2 
siRNA  
I/II  Compl
eted  
Sylentis  
NCT00725686, 
NCT00713518  
PF-
045236
55  
IVT  Naked 
siRNA  
Wet AMD  RTP801  I, II  Compl
eted  
Pﬁzer/Quar
k  
NCT00716014  TD101  Intralesi
onal  
Naked 
siRNA  
Pachyonychia 
congenita  
Keratin 6a 
N171K 
mutant 
mRNA  
Ib  Compl
eted  
TransDerm
/ IPCC  
NCT00882180, 
NCT01158079  
ALN-
VSP02  
IV  SNALP  Liver cancer, 
solid tumors  
KSP and 
VEGF  
I, I  Compl
eted  
Alnylam  
7 
 
NCT00554359, 
NCT00683553  
I5NP  IV  Naked 
siRNA  
AKI for major 
cardiovascular 
surgery  
P53  I, I  Compl
eted, 
termin
ated  
Quark 
Pharma  
NCT01148953  ALN-
TTR01  
IV  SNALP  TTR-mediated 
amyloidosis  
Transthyret
in  
I  Compl
eted  
Alnylam  
NCT00689065  CALA
A-01  
IV  RONDEL  Solid cancer  RRM2  I  Active  Calando 
Pharma  
NCT00466583  EZN-
2968  
IV  Naked 
LNA  
Advanced solid 
tumor, lymphoma  
HIF-1a  I  Compl
eted  
Santaris 
Pharma  
NCT01120288  EZN-
2968  
IV  Naked 
LNA  
Liver metastases  HIF-1a  I  Recrui
ting  
NCI  
NCT00672542  siRNA 
in 
dendriti
c cells  
Ex 
vivo, 
Intrader
mal  
Electropor
ation  
Metastatic 
melanoma  
Immunopro
teasome 
subunits 
LMP2, 
LMP7, 
MECL1  
I  Active  Duke 
University  
NCT01061840  FANG 
vaccine  
Ex 
vivo, 
Intrader
mal  
Electropor
ation  
Solid tumors  Bi-shRNA-
Furin and 
GM-CSF  
I  Recrui
ting  
Gradalis, 
Inc.  
NCT01064505  QPI-
1007  
IVT  Naked 
siRNA  
Optic atrophy  Caspase-2  I  Active  Quark 
Pharma  
NCT00938574  Atu027  IV  AtuPLEX  Advanced solid 
cancer  
PKN3  I  Compl
eted  
Silence 
Therapeuti
cs  
NCT01188785  siG12D 
LODER  
EUS 
biopsy 
needle  
LODER 
polymer  
Pancreatic ductal 
adenocarcinoma  
KRASG12
D  
I  Recrui
ting  
Silenseed 
Ltd  
NCT01262235  TKM-
080301  
IV  SNALP  Cancer  PLK1  I  Recrui
ting  
Tekmira  
NCT00927459  PRO-
040201  
IV  SNALP  Hypercholesterol
emia  
Apo B  I  Termi
nated  
Tekmira  
 
 
1.3 LIMITATIONS OF RNAi IN ONCOGENE THERAPY APPLICATIONS 
 The application of RNAi in clinical oncology is faced with several challenges.
4
 These 
include: poor delivery and cell permeability, immunostimulatory activity, non-selective (off-
targeting) gene silencing effects, poor metabolic stability and acute toxicity.
38
 For example, 
elevated immune responses following siRNA treatment were evaluated by the overexpression of 
inflammatory markers; interferon (INF) alpha and beta, cytokines such as interleukin-6 and 
tumor necrosis factor (TNF) alpha and chemokine induced by Toll-Like Receptors (TLR) 
agonists.
39
 Sequence similarities between the first 11 nucleotides of the antisense siRNA strand 
8 
 
and other genes can bring about off-target silencing.
40
 Moreover, the metabolic stability of the 
native siRNAs in biological media is poor, thereby minimizing its therapeutic index. This is 
especially the case in all types of RNA applications (vs. DNA) in biology and medicine. RNA 
contains a 2’-hydroxyl group which directs intramolecular transesterfication and hydrolysis of 
the vicinal phosphodiester bond leading to RNA isomerization and degradation during acidic, 
alkaline and enzyme catalyzed conditions (Figure 1.2).
41
 Direct cellular introduction of siRNAs 
results in transient gene silencing effects due to rapid degradation and renal clearance by 
endogenous serum ribonucleases (RNases) within 36-48 hours following siRNA transfection.
42 
 
 
Figure 1.2. RNA isomerization and cleavage steps during chemical and enzyme-catalyzed 
reactions. 
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Perhaps the most important obstacle to overcome for the clinical application of RNAi is 
the aspect of siRNA delivery. siRNAs are negatively charged as a result of their phosphate 
diester backbone. Moreover, they are bulky in size compared to small molecules, and 
consequently, siRNAs cannot penetrate the cell membrane by conventional diffusion.  In order to 
facilitate siRNA cellular uptake, (transfection) vectors must have the ability to effectively 
condense (package) siRNA and penetrate the amphiphilic lipid bilayer for efficient intracellular 
penetration and cytosolic release of siRNA for RNAi action.
43
 In order to fulfill these criteria, 
transfection vectors must: a)  be non-toxic and bio-compatible, b) condense siRNA efficiently, c) 
prevent siRNA degradation during circulation, d) deliver siRNA to target sites and avoid off-
target gene silencing, e) enhance uptake in cells and endosomal release once cell internalized, 
and f) facilitate the release of metabolically stable siRNAs to initiate potent RNAi effects. For 
example, in mouse studies, hydrodynamic injections of siRNA into the tail vein achieves the best 
RNAi responses (Figure 1.3).
44
 However, these studies also indicated that the delivered siRNAs 
in mice spread to various tissues including the liver and kidneys, resulting in aberrant gene 
silencing effects and cytotoxicities.  
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Figure 1.3. Methods of RNAi delivery in vivo.
44
 
 
Therefore, for safe and effective RNAi applications in humans, several limitations must be 
addressed.  
 
1.4 CURRENT METHODS FOR RNAi APPLICATION IN ONCOLOGY 
In an effort to address the drawbacks plaguing RNAi in the clinical settings, a series of 
improvements have been developed.
45
 Firstly, the design of the siRNAs have evolved from the 
native siRNA sequences (short 18-21 base-pairs dsRNAs) to those which retain important 
features for enhanced siRNA stability and activity. These include the 3’-overhang regions which 
facilitate the incorporation of phosphate groups at the 5’-ends by intracellular kinases, activating 
the siRNAs for assembly into RISC. Moreover, the site specific incorporation of adenosine and 
uridine base-pairs facilitates siRNA strand separation within the active site of RISC for mRNA 
recruitment and processing activity. Moreover, the site-specific incorporation of modified RNA, 
11 
 
namely the 2’-OMe RNA, within the seed region of the antisense siRNA strand have been shown 
to improve siRNA metabolic stability while minimizing off-target gene silencing effects and 
immunostimulatory activity (Figure 1.4).  
 
 
Figure 1.4. Design of effective siRNAs for clinical RNAi application
43-45 
 
The selected siRNAs are also screened against other gene targets to determine sequence 
homology that may lead to off-target gene silencing effects. For example, selected siRNAs (19-
22 base pairs), are typically rich in guanosine-cytosine (GC) content, to stabilize siRNA duplex 
formation while minimizing RNA self-folding or binding to non-specific mRNA targets.
46
 
Computer algorithms such as, AsiDesigner, used in conjunction with BLAST and FASTA may 
help design the optimal siRNA candidates.
47
 
The rise and development of automated solid-phase RNA synthesis
48
 has led to the rapid 
production of chemically derived siRNAs (Figure 1.5).
49
 Chemical siRNA synthesis allows the 
incorporation of chemical modification without restriction to alleviate problems associated with 
12 
 
poor nuclease resistance, cell permeability, immunostimulatory activity and off-target gene 
silencing effects of the native siRNA sequences.
38
 For example, bio-conjugation of siRNA with 
lipophilic molecules such as palmitic acid and cholesterol enables siRNA permeability in HeLa 
cells and potent anti-tumor effects in-vivo.
50
 Chemical modification of the 2’-position of the 
ribose sugar has also been shown to enhance resistance against RNase degradation, while 
increasing the half-life of modified siRNA in the cytosol leading to a more effective therapeutic 
index.
40
 Modification of the phosphodiester backbone to boranophosphate siRNA has also 
translated to beneficial RNAi effects, including gene silencing activity in HeLa cells for up to 
one week due to the enhanced metabolic stability of the backbone modified siRNAs.
51
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Figure 1.5. Chemically modified siRNAs and their bioconjugation with lipid moieties.
38,40,49-51 
 
To realize the full potential of synthetic siRNA in clinical applications of oncology, 
effective, bio-compatible and safe means of administration are necessary.
4,36,38
 Currently, 
transfection methods for the tissue penetration and intracellular localization of siRNAs are 
divided into two categories; those belonging to the viral and non-viral delivery systems (Figure 
1.6).  
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Figure 1.6. siRNA transfection methods for triggering RNAi in mammalian cells.
4 
 
 Viral transduction methods for siRNA gene silencing applications are typically applied 
with inoculated viruses whose capsid is filled with the siRNA component for specific 
administration at the localized tumor tissue site.
52 
The viral delivery systems (Table 1.3) are 
based on non-pathogenic strains of the Adenovirus, Lentivirus and Herpes Simplex Virus (HSV). 
In spite of their promising potential in oncologic gene therapy applications
53
, viral transduction 
methods are still hindered by some serious drawbacks, including those associated with a lack of 
tumor-target specificity, low siRNA transfer efficiency, and increased risk of cytotoxicity due to 
the infectious potential of the viral carrier.
4,52
 Consequently, greater attention to non-viral siRNA 
transfection methods has gained widespread practice in cancer gene therapy applications.
54
 
 Non-viral transfection agents are typically synthetic poly(cationic) amphiphiles that have 
the dual bio-activity of condensing siRNA, due to favorable ionic interactions, and penetrating 
the cell surface plasma membrane through necessary amphipathic interactions.
54
 Typically, the 
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siRNA:transfection agent internalizes within the cell by budding from the lipid bilayer through 
endosome formation and subsequent siRNA release occurs in the cytosol for RNAi activity.
55 
Since these vectors are synthetic in nature, they have several advantages over viral transduction 
agents. These include: low cost and ease of production and quality control, bio-compatibility, 
non-immunogenic and non-cytotoxic, and high siRNA uptake and release at the target tissue site 
for effective RNAi application.
54
 Fruitful examples of non-viral transfection agents in siRNA 
oncogene therapy include the use of cationic lipids, cell penetrating peptides, cationic polymers, 
dendrimers and the cancer-targeting peptides (Table 1.3). Polyethyleneimine, (PEI) is a cationic 
polymer that has been used to transfect siRNAs targeting the HER-2 receptor in breast cancer 
cells and in tumor-bearing mice with full bioactivity at completely nontoxic concentrations.
56
 A 
poly(ethyleneglycol) PEG-grafted monolamellar liposome in complex with siRNA generates a 
stabilized nucleic acid lipid particle, SNALP™, that has been commercialized by Tekmira 
Pharmaceuticals for siRNA applications, albeit with limited success due to the poor cell 
permeability properties of PEG and accelerated blood clearance in-vivo.
57
 Poly(cationic) 
hyperbranched molecules, dendrimers, such as those belonging to the poly(amidoamines) 
(PAMAM) and poly(lysines) have also been utilized as siRNA transfection agents.
43
 Cell 
penetrating peptides (CPPs) containing basic amino acid residues such as His, Lys and Arg have 
also been employed as delivery vehicles for siRNA cell internalization in cancer cells types 
including HeLa and Neuro2A neuroblastoma cancer cells.
58 
The application of peptides in siRNA delivery is especially attractive due to the 
biological nature of the transfection reagent. These may provide enhanced bio-compatibility and 
reduced cytotoxicities relative to the synthetic polymers. Moreover, the rise of automated solid-
phase peptide synthesis has provided a quick and efficient synthetic alternative for the 
16 
 
production of biologically active CPPs in bulk quantities (mg-g scales) for in-vivo siRNA 
application.
59
 In spite of their promising potential, CPP and the synthetic poly(cationic) polymers 
remain devoid of cancer cell targeting capabilities, thereby dispersing in all tissues leading to 
aberrant gene knockdown effects and toxicity.
60
 In order to overcome this limitation in oncogene 
therapy applications, cancer-targeting peptides, CTPs, have been identified through 
combinatorial solid-phase peptide synthesis and screening against cancer cell surface receptor 
targets
61
, or by phage display bio-panning methods that have facilitated the identification of short 
peptide ligands of tumor cell surface receptors.
62
 Thus, CTPs have been employed to selectively 
deliver cytotoxic anti-cancer drugs and siRNAs for targeted anti-cancer applications.
63
 
Moreover, combination approaches employing anti-cancer drugs and siRNAs targeting cancer 
cell surface antigens have demonstrated the most success and promise in translating cancer 
therapy from pre-clinical to clinical settings.
18,24,37
   
 
Table 1.3. siRNA delivery systems in RNAi oncogene therapy as modified from Uchino et al.
36
 
Delivery  Tissue  Route  RNA  
Viral vector        
Adenovirus Brain  ICV  AT1a, AT1b shRNA64  
Adenovirus  Muscles  IM  Anti-VEGF miRNA 
cluster
65
  
  Brain  Intrastriatal  mHTT shRNA
66
  
Lentivirus  Spinal cord  Intraspinal  SOD1 shRNA
67
  
Herpes 
simplex virus  
Dorsal root ganglia  Injection into the 
sciatic nerve  
Trpv1 shRNA
68
 
  Glioma  IT  EGFR shRNA
69
  
Non-viral 
vector 
      
Oligofectamine  Colon cancer  IP/IV  B-catenin siRNA
70
 
DOTAP  Liver, spleen  IV  GFP siRNA
71
  
LIC-101  Liver metastasis  IV/SC  BCL-2 siRNA
72
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PEI  Ovarian cancer  IP/SC  HER-2 siRNA
73
  
  Glioblastoma  IP/SC  PTN siRNA
74 
 
Nanoparticle        
SNALP  Ebola virus  IP/SC  ZEBOV siRNA
75
  
  Lung cancer  IV  miR-34a/let-7
76
  
RONDEL  Melanoma  IV  RRM2 siRNA
77
  
  Ewing’s sarcoma  IV  EWS-FLI 1 siRNA78  
AtuPLEX  Prostate/pancreatic  IV  PKN3 siRNA
79
  
DOTAP, 
cholesterol and 
PEG  
Melanoma  IV  c-Myc/MDM2/VEGF 
siRNA and miR-34a
80
  
Atelocollagen  Testicular cancer  IT  HST-1/FGF-4 siRNA
81
  
  Osteosarcoma  IV  miR-143
82
  
  Prostate cancer    miR-16
83
  
HDI  Liver  IV  HBV siRNA
84
  
Carbon 
nanotube  
Brain  Into the cerebral 
cortex  
Caspase-3
85
  
 
 
1.5 THESIS OBJECTIVES 
In spite of the growing number of siRNA applications in oncology, there remain few 
successful examples that have translated from the pre-clinical to clinical settings. Thus, there’s 
still an unmet need to develop more potent siRNA constructs and efficacious delivery systems in 
oncogene therapy.  In an attempt to improve the oncogene silencing efficacy of siRNAs, Chapter 
2 describes the semi-automated solid-phase synthesis of linear, branch and hyperbranch siRNAs 
targeting Glucose Regulated Protein of 78 kiloDalton (GRP78) expression. GRP78 is a 
biological marker in tumors, typically found over-expressed and cell surface localized on a 
variety of cancer cell types. The branch siRNA motifs were designed to contain the sense and 
antisense strands embedded within the same molecular structure to favor duplex stability. While, 
the hyperbranch siRNAs contain multiple siRNA sequences, targeting single or multiple sites of 
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GRP78 mRNA for a synergistic gene silencing effect. The ability to silence multiple oncogene 
sites with hyperbranch siRNAs provides a method for rapidly screening oncogene sequences and 
enhancing the mRNA silencing effect in our gene therapy strategy. Their synthesis is reliant on 
the incorporation of a branch point nucleotide that may direct the chemical synthesis of the 
higher-order branch and hyperbranch siRNAs on solid-phase. Methods and characterization data 
for the branch point nucleotide and novel GRP78-targeting siRNA sequences are described in 
Chapter 2. 
Following siRNA synthesis and characterization, Chapter 3 describes their bio-physical 
and structural properties. The fruitful application of siRNAs in the RNAi technology is 
dependent on the formation of stable siRNA hybrids in aqueous media that can adopt the 
prerequisite A-type helix for biological activity. Thermal denaturation and structural studies 
using UV-Vis and CD Spectroscopy, respectively, were used to identify the suitability of the 
siRNA constructs for the RNAi application. Interestingly, branch and hyperbranch siRNAs 
maintained the required hybrid stability and A-type helix for potential RNAi activity. 
In collaboration with Brittany Blackman and Christopher Parronchi, MSc and BSc 
students researching in the lab of Dr. Allan D. Blake, the RNAi activity of the siRNA constructs 
was evaluated in HepG2 liver cancer cells. The siRNAs were found to elicit effective silencing 
of GRP78 expression (50-60%) while stimulating modest effects on cancer cell death (~15%). 
The biological assays and results are discussed in Chapter 4, which highlights the suitability of 
the novel branch and hyperbranch siRNAs in RNAi applications. Attempts to extrapolate their 
full anti-cancer potential are also discussed in Chapter 5, by combining the siRNAs with CTPs 
targeting cell surface GRP78 expression on HepG2 liver cancer cells. The CTPs described in this 
study were made and characterized by Stesha Joseph, a PhD student researching in the lab of Dr. 
19 
 
David Sabatino.  The structural analyses of the CTP:siRNA complexes were partly contributed 
by Reeta Yadav, a PhD student researching in the lab of Dr. Uri Samuni, Queens College. Taken 
together, these preliminary results will highlight the first steps towards the development of a 
fruitful cancer-targeting gene therapy approach.     
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CHAPTER 2. SYNTHESIS AND CHARACTERIZATION OF LINEAR, 
BRANCH AND HYPERBRANCH siRNAs.  
2.1   ABSTRACT 
 A semi-automated solid phase synthesis method is described in this chapter for the rapid 
production of linear, branch and hyperbranch siRNAs. The branch and hyperbranch siRNAs are 
novel constructs disclosed for the first time in this thesis. These siRNAs were designed to 
improve gene silencing efficacy while expanding the scope of siRNA substrates that may trigger 
potent RNAi effects in-vivo. Significantly, the siRNAs were selected to target the Glucose 
Regulated Protein of 78 kilodalton (GRP78) mRNA for potent oncogene silencing effects in 
cancer cells. In this study, a solid phase synthesis method was developed using our Applied 
Biosystems™ (ABI) 3400 synthesizer (ABI) to yield a small library (17) of siRNAs. The 
siRNAs consisted of linear, V-shape, Y-branch and  hyperbranch motifs, the latter in which 
contained multiple siRNAs for synergistic GRP78 silencing effects in a representative tumor cell 
line. The various branch siRNAs were generated from either 5’-OLv 2’-or 3’-OMMT ribouridine 
phosphoramidite branchpoint nucleotides, to explore the influence of the branchpoint 
connectivities on siRNA structure and activity. Furthermore, the incorporation of 2’-OMe inserts 
within the siRNA sugar-phosphate backbone is proposed to improve efficacy while retaining 
metabolic stability in biological media. These siRNAs were synthesized in good yields (17-83%) 
and purities (≥90%) following ion pairing reverse-phase HPLC analysis and purification. 
Furthermore, the identities of the siRNAs were confirmed by molecular weight analyses using 
electrospray ionization mass spectrometry (ESI-MS, Novatia Inc, Newton PA). Denaturing and 
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native PAGE were finally used to respectively ascertain sequence purity and hybridization for 
bio-physical, structural studies and RNAi application.  
2.2 INTRODUCTION 
2.2.1 SOLID PHASE RNA SYNTHESIS 
The demand for synthetic siRNA has increased rapidly since the discovery of RNAi in 
order to satisfy applications in high-throughput gene screening and sequencing in addition to 
gene therapy.
1
 Consequently, the rise of solid phase RNA synthesis has led to the rapid 
production of native and modified siRNAs. At the heart of this synthetic procedure is the use of 
an insoluble polymer support, initially composed of a divinylbenzene cross-linked polystyrene 
(DVB-PS).
2
 This solid support was optimized
3 
and is now composed of controlled pore glass 
(CPG) with pore sizes ranging from 500-3000 Ả. The larger pore sizes facilitate the synthesis of 
lengthy and complex RNA sequences.
4
 The CPG is typically derivatized with long chain alkyl 
amino (LCAA) groups that facilitate the incorporation of linkers for the attachment of the 
starting RNA monomer.
3,5
 The CPG is typically composed of a 5’-dimethoxytrityl (5’-ODMT) 
2’-tert-butyldimethylsilyl (2’-OtBDMS) RNA bound to the succinyl linker LCAA CPG solid 
support (Figure 2.1, i). The 5’-ODMT group is acid labile (3% dichloroacetic acid in 
dichloromethane) and can be deprotected to determine the loading of RNA on the solid support 
by UV-Vis spectrophotometry (Figure 2.1, ii). The loading capacity is also an important 
component in dictating synthesis yields and efficiencies, with higher loading supports (i.e. 80-
100 mol/g) producing more product at the cost of lower synthetic efficiencies.6 The solid 
support is used to drive chemical reactions to completion by adding a large excess of reagents, 
while facilitating post reaction work-up procedures by simple filtrations and washing steps 
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leaving the RNA bound to the solid support. Thus, the solid support is necessary for generating 
full length RNA sequences in good crude yields and purities.  
 
Figure 2.1. i. Attachment of a protected RNA monomer on a succinyl linked LCAA-CPG. ii. 
Equation for determining the loading capacity (µmol/g) of RNA monomer attached to the solid 
support using UV-Vis spectrophotometry. 
 
2.2.2 RNA PHOSPHORAMIDITES FOR SOLID PHASE RNA SYNTHESIS 
The conventional RNA building blocks for automated solid phase synthesis are 
composed of an acid labile 5’-ODMT group, base sensitive protecting groups masking the 
exocyclic amines (e.g. N-Bz, N-Ac, N-iBu) on the nucleobases, a fluoride labile 2’-OtBDMS 
protecting group and a 3’-phosphoramidite which facilitates coupling reactions to the nascent 
support-bound RNA (Figure 2.2).
7
 Although these building blocks are most commonly used in 
the production of siRNAs and their analogs (as exemplified in this study),
31
 they remain limited 
in the production of lengthy, bio-active RNA (>80 nucleotides).
8,9
 This limitation is primarily 
attributed to the chemical nature of the bulky 2’-OTBDMS groups, which sterically hinders the 
coupling of the 3’-phosphoramidites leading to the concomitant formation of short failure 
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sequences that diminishes yields and purities. For this reason, a variety of 2’-protecting groups 
have been developed for ameliorating the solid phase synthesis of lengthy and complex RNA.
10 
As a best case example, a 110 nucleotide-long precursor mi-RNA has been produced with the 
use of the 2’-O-cyanoethoxymethyl (CEM) RNA phosphoramidite building blocks to provide 1.0 
mg (5.5% yield) of pure RNA product.
11
   
 
 
Figure 2.2. Structures of commercially available (Chemgenes Inc., Wilmington MA) RNA 
phosphoramidites and their protecting groups for automated solid phase RNA synthesis. 
 
2.2.3 AUTOMATED SOLID PHASE RNA SYNTHESIS 
The phosphoramidite RNA building blocks were instrumental to the development of the 
first automated solid phase synthesis of RNA, founded by Ogilvie and co-workers at McGill 
University during the 1980s.
12
 The introduction of the gene machine has ushered the rapid 
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production of small (microgram to milligram) and large (gram to kilogram) quantities of RNA 
for applications in biology and medicine.
13
 
The automated solid phase RNA synthesis cycle (Scheme 2.1) begins with a detritylation 
step, for the removal of the 5’-DMT group from the RNA monomer linked to the CPG support 
(Figure 2.1, i). The detritylation step is performed with a 90 second delivery of 3% 
dichloroacetic acid in dichloromethane, 3% DCA: DCM, followed by a DCM wash cycle to 
remove any residual DCA prior to the coupling reaction. The RNA phosphoramidites (Figure 
2.2, 2.2) are dissolved as 0.15 M solutions in anhydrous acetonitrile, MeCN, and mixed with a 
coupling reagent, 0.25 M 5-ethylthiotetrazole, ETT, in MeCN, for reaction with the support-
bound RNA. Typically, the coupling reaction for RNA synthesis takes place in 10 minutes (15 
minutes for riboguanosine due to the bulky protecting groups). The dinucleotide bound support is 
then washed with MeCN to remove the excess coupling reagent and phoshoramidite prior to the 
‘capping’ step. The capping cycle is performed for 12 seconds with (Cap A: 1:1:8 v/v/v acetic 
anhydride:pyridine:tetrahydrofuran, Cap B: 16% N-methyl imidazole in tetrahydrofuran) to 
prevent side reactions with uncoupled RNA. During the course of the RNA synthesis procedure 
this step generates failure sequences; short RNA fragments that must be removed by RNA 
purification. Fortunately, each automated synthesis cycle for RNA is optimized to about 97-98% 
efficiency, such that the accumulation of failure sequences during synthesis is minimal. 
Following capping, an oxidation step for 14 seconds with a 0.02 M oxidant (I2 in 75/20/5 v/v/v 
tetrahydrofuran/ pyridine/ water) converts the reactive phosphite triester to the more stable 
phosphate triester backbone. The support is then washed and dried with MeCN and argon prior 
to 5’-detritylation and continuation of the synthesis cycle until the desired sequence has been 
completed. Following synthesis, RNA is cleaved from the solid support and deprotected using 
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alkaline conditions, 1: 1 v/v ammonium hydroxide: methylamine (1: 1 AMA) for 10 minutes at 
65 
o
C. RNA sequences that contain the more resilient protecting groups (i.e. Gua N-iBu) require 
lengthier deprotection times, typically accomplished with 3 : 1 v/v ammonium hydroxide in 
ethanol (3 : 1 NH4OH:EtOH) for 16 hours at 55 
o
C. The alkaline solution is volatile and is 
evaporated on a Speedvac
®
 concentrator. The crude RNA can be recovered from the CPG using 
autoclaved distilled water. The RNA is then concentrated and treated with a 1:1 v/v 
dimethylsulfoxide:triethylamine trihydrofluoride (1:1 DMSO:TREAT.3HF, 125 µL) to complete 
the 2’-desilylation reaction at 65 °C for 90 min. Following reaction, RNA is precipitated from 
the mixture using 3 M NaOAc (25 µL) in n-BuOH (1 mL), isolated by centrifugation and re-
dissolved in autoclaved water for analyses and purification using anion exchange, AE, or reverse 
phase, RP, HPLC and with polyacrylamide gel electrophoresis, PAGE.  
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Scheme 2.1. Automated solid phase RNA synthesis cycle. 
2.2.4 ANALYSIS AND PURIFICATION OF SYNTHETIC RNA BY HPLC 
High Performance Liquid Chromatography (HPLC) is commonly implicated in RNA 
analysis and purification. This includes denaturing (single-strand RNA) and non-denaturing 
(double-strand siRNA) methods using anion exchange
20
 (AE) and ion pairing reverse phase
21
 (IP 
RP) HPLC.  
AE HPLC relies on the separation of RNA based on favorable ionic interactions between 
the negatively charged phosphodiester backbone and the positively charged anion exchange 
resin. An eluent system, typically composed of aqueous perchlorate salts (i.e. 1 M NaClO4 or 1 
M LiClO4) is used to disrupt the ionic interactions between the RNA and resin, which gradually 
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begins to elute the RNA from the column.  The lengthier RNA sequences are most retained on 
the stationary phase and elute with extended retention times, while the shorter ones with fewer 
phosphate groups elute faster on the column. In a typical AE HPLC chromatogram, (Figure 2.3, 
a), the shorter RNA sequences (labeled failure sequences) elute prior to the desired RNA product 
in crude purities ranging from 70-95%, which is dependent on the nature and length of the 
synthesized sequence. Following isolation of the desired RNA product, a desalting step 
(Sephadex G-25 size exclusion chromatography) is necessary to remove the salt contaminants 
from the purified RNA. 
RP HPLC employs a column packed with a non-polar stationary phase (e.g. C18) which 
facilitates the separation of RNA based on favorable hydrophobic interactions. In order for this 
separation to occur, the anionic RNA phosphodiester backbone must be neutralized by the 
mobile phase, typically an ion-pairing agent composed of an organic alkylammonium salt (e.g. 
triethylammonium acetate, TEAA). This allows for the hydrophobic RNA nucleobases to 
interact with the stationary phase of the column. A combination of ion-pairing buffer in organic 
solvent (e.g. MeCN) allows for slow elution and separation of the RNA components in the crude 
reaction mixture. A typical IP RP HPLC chromatogram, (Figure 2.3, b), improves the separation 
of failure sequences, including the RNAs that have failed to incorporate the final 
phosphoramidite during solid phase RNA synthesis. These n-1 failure sequences are often 
challenging to remove from the desired product. Additionally, the incorporation of an extra 
phosphoramidite or incomplete deprotection may also result in the appearance of longer (n+1) 
sequences. In this case, IP RP HPLC may allow for better separation and purity of the targeted 
RNA sequence relative to AE HPLC (Figure 2.3). Furthermore, the eluent system in IP RP 
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HPLC is volatile, facilitating sample concentration and isolation of pure RNA for 
characterization. 
 
Figure 2.3. AE and IP RP HPLC analysis of RNA. Representative chromatograms of (A) AE 
and (B) IP RP HPLC analysis of RNA showing the failure sequences eluting first followed by 
the desired RNA and n+1 sequences resulting from incomplete deprotection or multiple 
couplings.
20,21
  
 
 The application of AE and IP RP HPLC in the analysis and purification of single strand 
RNA is accomplished at elevated temperatures (~60 
o
C). These conditions denature the H-
bonding interactions that are responsible for RNA secondary structures. Interestingly, IP RP 
HPLC has been commonly applied for the analysis and purification of double-stranded siRNA.
21
 
In this case, IP RP HPLC conditions are performed at ambient temperatures (~22 
o
C) that 
maintain the integrity of the siRNA duplex structure (Figure 2.4). These methods are widely 
applicable for the analysis and purification of siRNA at a detection wavelength of 260 nm.  
 [n+1] 
[n-1] 
Failure sequences 
A B 
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Figure 2.4. IP RP HPLC analysis of a double stranded siRNA eluted on a Waters C18 reverse 
phase column with eluent gradient from 35-85% B in 10 minutes, 0.2 mL/min, 20 
o
C. With 
solvent A: 100 mM TEAA pH 7 and B: 20% MeCN in 100 mM TEAA pH 7. Detection at 260 
nm.
21 
 
2.2.5 ANALYSIS AND PURIFICATION OF SYNTHETIC RNA BY PAGE 
Gel electrophoresis has been applied for the analysis and separation of medium length (5 
-25 nucleotides) to lengthy (>30 nucleotides) RNA.
22
 In this technique, RNA samples (0.05 – 
0.30 O.D. units for analytical and 5.0-15 O.D. units for preparative gel electrophoresis) are 
suspended in a gel loading buffer that either retains (sucrose) or denatures (formamide) RNA 
secondary structures. A 10-20% polyacrylamide gel is typically used in the analyses of lengthy 
RNA (> 80 nucleotides) whereas a 20-24% gel is most commonly used in the separation and 
purification of siRNA (18-21 nucleotides). A native polyacrylamide gel electrophoresis (PAGE) 
is used to track the formation of RNA structures (in this case double-stranded siRNAs) or the 
binding interaction between ligand and RNA.
23
 For example, a poly(arginine) peptide sequence 
was added to siRNA and native PAGE was used to track the optimal stoichiometric ratios for 
complex formation (Figure 2.5, i).
24
 Alternatively, a denaturing PAGE uses urea in the gel 
matrix to help denature non-covalent bonding interactions. This facilitates the migration of RNA 
across an electric field generated from an applied voltage and current. This result in efficient 
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separation of crude samples for analysis and purification.
25
 The trend for RNA separation on 
PAGE is based on size, shape and charge, with the lengthier RNA sequences most retained and 
the shorter ones migrating at a faster rate (Figure 2.5, ii). Following electrophoresis, RNA may 
be visualized under UV shadowing (260 nm) or with the addition of an intercalating dye such as 
ethidium bromide, which makes a purple colored complex with RNA. For preparative PAGE, the 
desired RNA band is excised from the gel, transferred to a sterile tube and extracted in 
autoclaved water. Typical gel recoveries range from 40-60% and require an additional desalting 
step (Sephadex G-25 size exclusion chromatography) prior to mass spectrometry, structure 
analyses and biological studies.   
 
Figure 2.5. Polyacylamide gel electrophoresis of i. siRNA:poly(arginine) complexes under 
native conditions, 20% polyacrylamide gel with ethidium bromide staining and ii. Crude RNA 
analysis using denaturing conditions, 24% polyacrylamide gel using 7 M urea and RNA 
visualization at 260 nm.
22-25
 
 
 
 
 
2.2.6 CHARACTERIZATION OF SYNTHETIC RNA BY MASS SPECTROMETRY  
Mass spectroscopy (MS) is the most commonly used analytical technique for RNA 
characterization by providing mass to charge ratios (m/z) of the observed ions and fragmentation 
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patterns. This characterization method is typically coupled with HPLC, providing the basis for 
LC/MS analysis and characterization of RNA samples in high-throughput sequences.
26
  The most 
suitable types of MS analyses for RNA characterization provides mild sample ionization with 
little fragmentation. These include: electrospray ionization (ESI) and matrix assisted laser 
desorption/ionization time of flight (MALDI-TOF) mass spectrometry.
27,28
 MALDI-TOF MS 
requires the RNA sample to be embedded within a suitable matrix, typically composed of aza-
thiothymine/spermine and L-fucose, which is then subjected to a UV laser beam causing sample 
absorption, followed by desorption from the matrix and ionization.
29
 The ions are then separated 
and detected by the TOF-MS producing a mass spectrum of the RNA sample in positive 
(protonated) or negative (deprotonated) mode. MALDI-TOF MS is a mild ionization method that 
is perfectly suitable for the target molecular weight detection of large RNA samples (≥300 kDa) 
in the pico-femtomolar range.
28,29
  
In ESI MS, RNA samples are dissolved in water (µM solutions) and turned into a fine 
spray of charged droplets by a high voltage produced by the ESI source. This desolves the 
samples and creates ions that are sorted by a quadrupole mass analyzer and detected by some 
type of electron multiplier detector. Typically, an eluent system that facilitate sample ionization 
and avoids ion quenching can be used. For example, buffers consisting of triethylamine and 
hexafluoroisopropanol (TEA:HFIP) are usually well suited for siRNA LC/MS applications.
27
 
 
 
2.2.7 APPLICATIONS OF SYNTHETIC siRNAs AND ANALOGS 
 The power of automated solid phase RNA synthesis has led to the rapid generation of 
siRNAs and analogs for high-throughput screening assays against gene targets and applications 
41 
 
in gene therapy for fighting human malignancies such as cancer.
1
 Among the trove of examples 
represented in the literature, a few are discussed herein to highlight their significance in 
elucidating complex biological process and potentially treating some of the most debilitating 
disorders.  
Fluorescent tags such as Alexa Fluor 488 and Cy5 have been conjugated to the 3’-ends of 
the sense and antisense strands, respectively, by solid phase RNA synthesis. The fluorescently 
labeled siRNAs were tracked in live Huh-7 cells with a laser confocal fluorescence microscope, 
which displayed real-time images of the siRNAs targeting nuclear 7SK, U6 and cytosolic NS3 
mRNA.
14
 These results demonstrated for the first time a responsive RNAi pathway in the 
nucleus of live cells (Figure 2.6).     
  
 
Figure 2.6. Live cell imaging with fluorescently labeled siRNAs (a: Cy5 labeled siRNA, red > 
635 nm b: Alexa Fluor labeled siRNA, green 495-520 nm) in the nucleus (c: DAPI blue dye 
stain) of Huh-7 human cells. Figure adapted from reference 14. 
 
Similarly, a single molecule fluorescence resonance energy transfer (FRET) assay was 
recently developed to determine the mechanism of Argonaute (Ago) binding and cleavage 
activity of a single-stranded siRNA (antisense strand) in complex with a target mRNA strand.
15
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The Ago enzyme has been associated with mRNA processing, possessing the ability to 
selectively degrade the mRNA component during the RNAi pathway. Despite this knowledge, 
the mechanistic and kinetic aspects of Ago binding and cleavage activity of mRNA substrate 
remain unclear. In an effort to elucidate the mechanism of Ago activity, an antisense strand was 
conjugated with an acceptor Cy5 red (> 635 nm) fluorescent tag; whereas a target mRNA strand 
was conjugated with an acceptor Cy3 green (535-635 nm) fluorescent tag and a biotin label for 
binding to a streptavidin functionalized quartz slide. The antisense strand was mixed with Ago 
and incubated with the target mRNA bound to the solid support. Single molecule images at fixed 
time intervals were collected with a fluorescent microscope to determine the mRNA binding and 
cleavage activity of the Ago enzyme (Figure 2.7). 
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Figure 2.7. Single molecule FRET experiment for determining the mechanism of Ago action 
with a target mRNA substrate. a) Conjugation of antisense siRNA strand and target mRNA 
strand with fluorescent dyes (Cy 5, red >635 nm, and Cy3, green 535-635 nm) and b) 
immobilization of biotin labeled mRNA strand onto a streptavidin functionalized surface for c) 
FRET monitoring Ago activity. Figure adapted from reference 15.    
 
The application of synthetic siRNAs in gene therapy has received even greater 
recognition, with countless examples being published in the literature on a weekly basis. Among 
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these fruitful examples, lipophilic siRNAs (Figure 2.8, 2.3) have been made by solid phase RNA 
synthesis and demonstrated effective cellular uptake and gene silencing effects in vivo.
16 
 
Furthermore,  elaborate combinatorial approaches have also been developed to improve the 
efficacy of siRNAs in the RNAi mechanism. A series of reports have demonstrated enhanced 
silencing effects of self-assembled RNA containing multiple siRNAs, thereby potently inhibiting 
gene expression in a synergistic manner. For example, a reducible disulfide siRNA dimer, 
linking an siRNA motif targeting the green fluorescent protein (GFP) and another targeting 
vascular endothelial growth factor (VEGF) expression demonstrated enhanced cellular uptake 
and gene silencing effects in vitro relative to the monomeric form (Figure 2.8, 2.4).
17
 A 
tripartite-interfering RNA (tiRNA) (Figure 2.8, 2.5) displayed more potent and longer lasting 
activity compared to the linear control siRNAs.
18
 Surprisingly, the self-assembled tiRNA 
targeting the Lamin, DBP and TIG3 genes did not require processing into its constituent siRNAs 
for gene silencing activity in mammalian cells.  Lastly, branch siRNA nanostructures (Figure 
2.8, 2.6) displaying multiple substrates for RNAi activity also retained the same trend, soliciting 
greater silencing effects relative to the linear siRNA controls.
19
 These siRNAs effectively 
demonstrate that the RNAi mechanism is tolerant of modifications that may lead to more potent 
gene silencing effects in vivo. 
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Figure 2.8. Modified siRNAs for RNAi application.
16-19
 a) Lipophilic siRNAs displayed 
enhanced cell delivery and gene silencing activity in vivo. b) Dimerized siRNA displayed 
enhanced gene knockdown effects relative to the linear siRNA controls. c) tiRNA self-assembled 
multiple siRNA sequences for synergistic gene silencing effects. d) siRNA nanostructures 
exhibit potent RNAi activity.    
 
2.3 PROJECT OBJECTIVES 
 Inspired by these methods, this chapter describes the design, solid phase synthesis and 
characterization of a new class of siRNA nanostructures (Figure 2.9). Based on the putative 
linear siRNA sequences for silencing GRP78 expression in vitro, 2.7; 
42
 V-shape, 2.8, Y-branch, 
2.9, and   hyperbranch, 2.10-2.11, siRNAs are proposed to confer greater siRNA stability 
while enhancing its GRP78 silencing effects in cancer cells. In our design, V- and Y-branch 
siRNAs were inspired by the use of short hairpin RNA (shRNA) in potent RNAi applications.
30
 
The V- and Y-branch siRNAs described in this chapter contain single branchpoint nucleotides 
which combines the sense and antisense strands within single molecular structures (Figure 2.9, 
2.8 and 2.9, respectively). These motifs are proposed to maintain more stable hybrid structures 
relative to their linear controls. Hyperbranch siRNAs were inspired by combination approaches 
(Figure 2.8), which featured the delivery of multiple siRNAs to effect more potent RNAi 
activity relative to the linear controls targeting single mRNA expression sites.
16-19
 The 
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hyperbranch siRNAs disclosed in this chapter were designed to contain two siRNA motifs 
embedded within the same molecular structure by the branchpoint nucleotides. These sequences 
were conceived to target single or double sites of GRP78 oncogene expression in cancer cells 
(Figure 2.9, 2.10, 2.11). This chapter highlights an optimized solid phase synthesis method for 
their preparation and analytical techniques for characterization. These studies are essential to 
obtain pure siRNA samples for their bio-physical properties, structure elucidation and RNAi 
application.  
 
Figure 2.9. Structures of siRNAs designed, synthesized and characterized in this study. 
 
 
 
 
 
 
 
47 
 
2.4 RESULTS AND DISCUSSION 
2.4.1 SYNTHESIS AND CHARACTERIZATION OF BRANCHPOINT NUCLEOTIDES 
Branchpoint nucleotides have been incorporated within RNA to generate higher-ordered 
and biologically relevant structures, such as those belonging to the branch, hyperbranch and 
lariat RNA.
31,32
 These RNA motifs have been shown to have significant biological activity and 
serve as useful probes for exploring the influence of RNA structure on cell biology. For example, 
branch and lariat RNA have been synthesized and applied as inhibitors of mRNA splicing events 
for potential anti-cancer utility.
33
 Moreover, we have recently demonstrated that branch and 
hyperbranch short-interfering RNA (siRNA) potently silence oncogenic Glucose Regulated 
Protein of 78 kilodalton (GRP78) expression leading to cell death activity in HepG2 liver cancer 
cells.
31
  
A variety of branch point phosphoramidites have been synthesized in the literature and 
some are commercially available. For example, a branch point nucleoside composed of a 5’-
OMMT N-Bz adenosine 2’,3’-bisphosphoramidite has been made for the solution phase 
assembly of symmetrically branched RNA trinucleotides (Figure 2.10, 2.12).
34 
 The same branch 
point synthon has been applied for the solid-phase assembly of branch RNA structures, albeit 
composed of homopolymeric sequences.
35 
Orthogonally protected branch point 
phosphoramidites have been developed for the preparation of asymmetric branch and 
hyperbranch RNA in addition to lariat structures on solid phase.
19a,31,32,36
 For example, 5’-ODMT 
2’-Fpmp, and 2’-OtBDMS branch point phosphoramidites (Figure 2.10, 2.13, 2.14) have been 
developed for the solid-phase synthesis of branch DNA/RNA chimeras, referred to as msDNA; a 
rare form of genetic material found in some bacteria.
37
  Although these methods are suitable for 
the production of asymmetrically branched oligonucleotides, they lack in their ability to generate 
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asymmetric RNA. Towards this goal, acyclic linkers containing orthogonal protecting groups 
(Figure 2.10, 2.15) have been marketed for the production of branch and self-assembled RNA.
19a 
Most recently, the development of 5’-OLv 2’OMMT ribouridine phosphoramidites31,36 and 
related analogs
32
 (Figure 2.10, 2.16, 2.17-2.19) have been employed for the asymmetric solid 
phase synthesis of biologically relevant branch, hyperbranch and lariat RNA species. The former 
is especially practical for generating lengthy (> 80 nucleotides) biologically active RNA 
nanostructures for applications in biology
31-33
, theranostics
38
 and supramolecular
19
 chemistry. 
Thus, the branchpoint phosphoramidites containing the 5’-OLv and 2’-OMMT orthogonal 
protecting groups are a focal point of the proposed research study (Figure 2.10, 2.16). 
 
 
Figure 2.10. Branchpoint nucleotide phosphoramidites used in the preparation of branch, 
hyperbranch and lariat RNA.
19a,31-36
  
 
 The solution-phase synthesis of branchpoint amidites, 2.16 and 2.24, 5’-O-levulinyl 2’ 
and 3’-O- monomethyoxytrityl ribouridine phosphoramidites (Scheme 2.2) was completed by a 
solution phase synthesis method based on literature precedence.
36
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Scheme 2.2. Reaction and Conditions: (i). Lv2O, Novozyme
®
 435, 1,4-dioxane, 22 
o
C, 
overnight, 80%. (ii). MMT-Cl, AgNO3, THF, pyridine. 22 
o
C, 3 h, 2.22: 40% and 2.23: 20%, 
(iii). Cl-P(OCE)N(iPr)2, Et-N(iPr)2, THF, 22 
o
C, 3 h, 2.16: 55% and 2.24: 60%. 
 
The solution phase synthesis of branchpoint phosphoramidites, 2.16 and 2.24, was 
completed via a 3 step synthesis procedure featuring: (a) chemo-enzymatic 5′-levulination of 
ribouridine, (b) tritylation and (c) phosphitylation (Scheme 2.2). The first step entailed the 
regioselective chemo-enzymatic 5’-levulination of ribouridine using Novozyme® 435 
immobilized on lipase.
39 
This reaction is preferred over chemical levulination which produces 
multiple levulinated products upon treatment of ribouridine with levulinic anhydride and 1,4-
diazabicyclo[2.2.2]octane (DABCO).
40
 Instead, the chemo-enzymatic approach produced 
selectively the desired 5′-levulinyl ribouridine, 2.21, in 80% yield. With pure product in hand, 
2.21, was tritylated using monomethoxytrityl chloride to give both the 2′ and 3′ tritylated 
regioisomers (2.22 and 2.23) respectively collected in purified yields of 40% and 20%. The 
reaction was found to favor the desired 2′-regioisomer due to the enhanced nucleophilicity of the 
2′- over the 3′-hydroxyl.41 The identity of the pure regioisomers was ascertained by NMR, in 
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which a COSY correlation cross-peak was used to explicitly assign the 2’ and 3’-hydroxyl 
groups (Figure 2.11). The regioisomers, 2.22 and 2.23, were phosphitylated separately to their 
branchpoint phosphoramidites in purified yields of 55% and 60%. In this case, 
31
P NMR was 
used to assess the purity of 5′-Lv 2′-OMMT and 5′-Lv 3′-OMMT ribouridine phosphoramidite 
diastereomers, 2.16 and 2.24, respectively (Figure 2.12). These are perfectly suitable for solid 
phase RNA synthesis, in which the synthetic method removes the chirality at phosphorous. With 
pure branchpoint phosphoramidites in hand, opportunity now exists for developing a solid phase 
synthesis procedure for branch and hyperbranch siRNAs.  
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2.4.2 SOLID PHASE SYNTHESIS OF BRANCH AND HYPERBRANCH siRNAs. 
The siRNA sequences synthesized in this study (Table 2.1) are based on the target 
nucleotides for down-regulating Glucose Regulated Protein 78 (GRP78) expression in human 
cancer cells.
42 
 An iterative protocol for the solid-phase synthesis of branch and hyperbranch 
siRNAs targeting GRP78 oncogenes is next described (Scheme 2.3). This solid phase synthesis 
approach entails linear RNA synthesis up to the branchpoint nucleotide 2.16. The next reaction 
requires a decyanoethylation step, which liberates the phosphate protecting groups affording a 
more stable phosphate diester, 2.27, relative to the triester, 2.26, prior to acid detritylation and 
chain extension reactions.
37
 An additional acetylation step caps the 3’ or 5’-ends of the ‘V-
shaped’ RNA molecule, 2.28, and prevents additional coupling reactions by acetylating the 
terminal hydroxyl group. A manual delevulination procedure is used to liberate the branchpoint 
5′-hydroxyl31,32,36 and the branch siRNA, 2.29, is completed by automated RNA synthesis. This 
cycle may be repeated for the generation of hyperbranch siRNA sequences (Table 2.1, 
sequences 6, 7, 10, 11, 16, 17). Additionally, this methodology lends itself to the incorporation 
of modified nucleic acids such as the 2′-OMe RNAs for improving siRNA pharmacokinetic 
properties (Table 2.1, sequences 12-17).
42 
Moreover, branch and hyperbranch siRNAs consisting 
of the branchpoint nucleotide, 2.24, were also synthesized to explore the influence of 
branchpoint connectivities on siRNA structure and RNAi activity (Table 2.1, sequences 8-11). 
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Scheme 2.3. Solid phase branch RNA synthesis method. 
The synthesis of linear GRP78 siRNA sequences (Table 2.1, sequences 1-3) were 
accomplished on a 500 Å CPG support. These sequences were prepared as suitable controls, in 
order to validate their GRP78 silencing and cancer cell death activity.
42
 The V-shape and Y-
branch siRNAs (Table 2.1, sequences 4-5) necessitated the use of a 1000 Å CPG support, which 
led to the first successful isolation of the V-shape (Figure 2.13) and subsequently Y-branch  
siRNA. For the solid phase assembly of the hyperbranch siRNAs (Table 2.1, sequences 6-7), an 
optimized synthesis method was established with 2000 Å CPG. The synthesis method featured 
fast deprotecting RNA amidites (which replace the N-Bz/N-iBu protecting groups for N-Ac, N-
iPr-Pac), milder oxidant (0.02 M iodine/water/pyridine/THF) and short, pulsating detritylation 
steps (60 and 30 sec) with 3% DCA:DCM (Figure 2.14). The anti-parallel orientations of the 
complementary siRNAs were maintained by introducing un-natural 2’,3’ and 3’,3’-
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phosphodiester linkages at the branchpoint nucleotides, and the use of reverse 5’-
phosphoramidites.
31,32,36,44
 Incredibly, these changes led to the successful synthesis of an 86-mer 
hyperbranch siRNAs (Table 2.1, sequences 6-7). Following this optimized procedure, the 
efficient solid phase synthesis of V-shape, Y-branch and  hyperbranch siRNAs composed 
from the branchpoint nucleotide, 2.24, was realized (Table 2.1, sequences 8-11). The 2’-OMe 
series proved to be a synthetic challenge due to the mixed sequence compositions. In spite of this 
challenge, the 2’-OMe siRNAs (Table 2.1, sequences 12-17) were synthesized in sufficient 
yields for structure and biological applications.  
Following synthesis, RNA was cleaved from the solid support and deprotected using 1:1 
v/v ammonium hydroxide / methylamine for 20 min at 65 
o
C. The crude samples were suspended 
in a mixture of 1:1 v/v dimethylsulfoxide/triethylamine trihydrofluoride for 2 h at 65 
o
C to 
complete the 2’-desilylation reaction. Following post-synthesis work-up conditions siRNAs, 
were analyzed and purified by IP RP HPLC and PAGE. 
 
 2.4.3 ANALYSIS, PURIFICATION AND CHARACTERIZATION OF siRNAs. 
 The analysis of crude siRNAs by IP RP HPLC generally demonstrated chromatograms 
containing lower molecular weight failure sequences with shorter retention times followed by the 
desired siRNAs. The failure sequences for linear siRNAs resulted from incomplete couplings 
that were typically held to a minimum (<10%) facilitating sample purification. In the case of the 
branch and hyperbranch siRNAs, the failure sequences predominantly consisted of incomplete 
couplings at the branchpoint nucleotides. This feature can be attributed to the chemically labile 
and sterically encumbered vicinal 2’,3’ or 3’,3’-phosphodiester linkages at the branchpoint 
positions.
36 
 These branchpoint connectivities have been found to be especially sensitive to acid 
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and base catalyzed hydrolysis at elevated temperatures. This effect diminishes yields and crude 
purities (≤50%) for the lengthy branch and hyperbranch siRNAs. In spite of these limitations, our 
optimized synthesis protocol affords sufficient quantities of siRNAs for analysis and purification, 
yielding pure samples (Figures, 2.13, 2.14) for bio-physical, structure and biological studies.   
 
 
Figure 2.13. IP RP LC/MS analysis of a pure V-shape siRNA (Table 2.1, sequence 4). 
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Figure 2.14. IP RP LC/MS analysis of a pure hyperbranch siRNA (Table 2.1, sequence 7). 
 
With purified sequences in hand, native and denaturing PAGE were conducted in order to 
validate siRNA purity and hybridization into double-stranded form (Figure 2.15). Under native 
conditions, branch and hyperbranched siRNAs (Table 2.1, 4-11, 14-15) showed slower 
electrophoretic mobility and the formation of stable higher-order complexes relative to their 
linear controls. Alternatively, under denaturing conditions, most siRNAs migrated as their linear 
single-stranded oligonucleotides. Exceptionally, branch and hyperbranch siRNAs (Table 2.1, 4-
11, 14-15) maintained stable higher-order complexes under denaturing conditions, suggesting 
stable H-bonding base-pairs between the two complementary strands. These results are not 
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entirely surprising, considering RNA hairpins possess thermodynamically more stable folded 
structures relative to their linear double-stranded sequences.
43
  
 
 
 
Figure 2.15. Native and denaturing PAGE analyses of siRNAs synthesized in this study. A, C 
and E: denaturing (7 M urea) 18% PAGE; B, D and F: native (no urea) 18% PAGE of linear, 
branch and hyperbranch siRNAs (Table 2.1 sequences 1-15).  
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a
Sequences 1, 4, 5, 6, 8, 9, 10, and 12 derived from nucleotides 1236-1254 containing the 
initiation codon for GRP78 mRNA
42
; 
b
Sequences 2, and 13 derived from nucleotides 1887-1906 
of GRP78 mRNA
42
; 
c
Sequence 3 is a non-specific control; 
 d
Sequences 7, 11, 17 contains 
sequence derived from 1 and 2; 
e
Sequences 4-7 and 14-17 are composed with branchpoint 
nucleotide 2.16, sequences 8-11 are composed with branchpoint nucleotide 2.24, and sequences 
12-17 have 2’OMe inserts at the underlined positions; fDetermined by IP RP HPLC using 80-
20% 0.1 mM TEAA in MeCN pH: 7.2 (23 min); 
h
Determined by UV-Vis spectroscopy; 
g
Observed mass (calculated mass) determined by ESI-MS in negative mode (Dr. Mark Hail, 
Novatia LLC, Newtown, PA).  
 
2.5 CONCLUSIONS 
 In conclusion, we have demonstrated the effective synthesis, purification and 
characterization of a novel class of siRNA molecules. In this study, branch and hyperbranch 
siRNAs were effectively prepared by solid phase RNA synthesis. These sequences were 
analyzed and purified by IP RP HPLC and by PAGE. The identities of the pure siRNA samples 
were confirmed by molecular weight analyses using ESI-MS (Dr. Mark Hail, Novatia LLC, 
Newtown, PA). Interestingly, the branch and hyperbranch siRNAs conferred stable single 
molecular hybrid structures as detected by native and denaturing PAGE analyses. These results 
effectively leads into the bio-physical and structural properties of the synthetic siRNAs, a focal 
point in Chapter 3 of this thesis.  
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2.7 EXPERIMENTAL SECTION 
 
2.7.1 GENERAL METHODS   
Chemical synthesis reagents and solvents were obtained from ChemGenes, Aldrich and 
VWR and used as received. Solid phase oligonucleotides synthesis reagents and materials were 
obtained from ChemGenes or Glen Research Inc. and also used without further purification. 
HPLC grade solvents for chromatography were purchased from EMI Biosciences. Analytical 
thin-layer chromatography (TLC) was performed on aluminum-backed silica gel plates (Merck 
60 F254). TLCs were visualized under UV shadowing (260 nm) or staining (10% 
H2SO4/MeOH). Compound purification using silica gel chromatography was performed on 230-
400 mesh silica (Sorbent Technologies). Molecular weights for 2.16, 2.20-2.24 were measured as 
direct injections on a Hewlett Packard series 1100 MSD equipped with ESI as ion-source in 
positive mode using 50/50 v/v MeOH/H2O at a flow-rate of 1 mL/min. Nuclear magnetic 
resonance spectra (
1
H, 
13
C, 
31
P COSY, HMQC NMR) were recorded on an OXFORD NMR 
AS500 spectrophotometer. The NMR spectra were obtained at ambient temperature using either 
an indirect pulse-field gradient (ID-PFG) or a switchable pulse-field gradient (SW-PFG) probe. 
The obtained data was processed using VNMRJ software (version 2.2). The 
1
H and 
13
C 
assignments were based on gCOSY and gHMQC NMR correlation experiments.  
 
2.7.2 SYNTHESIS OF THE BRANCHPOINT PHOSPHORAMIDITES, 2.16 AND 2.24  
5’-O-levulinyl ribouridine (2.21): Levulinic acid (5.0 mL, 49 mmol) and 1 M N,N-
dicyclohexylcarbodiimide (DCC) in dichloromethane (6.6 mL, 40 mmol) were stirred together in 
260 mL of anhydrous diethyl ether to generate levulinic anhydride (Lv2O). The reaction was run 
at room temperature (22 °C) under N2 atmosphere for 5 hours. The byproduct (DCU) was 
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removed by vacuum filtration and the filtrate was evaporated into viscous oil. In a second flask, 
ribouridine (2.15 g, 8.8 mmol) was vacuum dried for 5 hours and flushed with nitrogen before 
being suspended in 40 mL of anhydrous dioxane with resin-bound lipase enzyme, Novozyme
®
 
435 (3 g). Crude Lv2O was dissolved in dioxane (160 mL) and added in 20 mL fractions over a 
period of one hour to the flask containing the ribouridine and enzyme in dioxane. The chemo-
enzymatic reaction was run overnight (12-16 h) at 22 °C (room temperature) under N2. The 
reaction progress was monitored by TLC (10% MeOH in DCM) which confirmed 100 % 
conversion of starting material to product and the appearance of two non-polar product (Rf: 0.48 
and 0.35). The resin-bound lipase was filtered, washed (MeOH) and recycled for additional use. 
The filtrate was concentrated and purified by silica gel column chromatograpy (5-10 MeOH: 
DCM) to isolate the product in 80% yield.  
1
H NMR (2.21, 500 MHz, DMSO-d6):  11.32 (1H, bs, NH), 7.62 (1H, d, J = 8.5 Hz, H6), 5.66 
(1H, d, J = 7.5 Hz, H5), 5.74 (1H, d, J = 5 Hz, H1’), 4.24 (1H, dd, J = 7.5 Hz, H5’), 4.14 (1H, dd, 
J = 12, 7.5 Hz, H5”), 4.06 (1H, t, J = 10 Hz, H2’), 3.95 (1H, bs, H3’), 3.32 (1H, s, H4’),  2.71 
(2H, s, Lv CH2), 2.61 (2H, s, Lv CH2), 2.08 (3H, s, Lv CH3); 
13
C NMR (2.21, 125 MHz, CDCL3-
d1): 212.1 (CO), 177.4 (CO), 168.3 (CO), 155.8 (CO), 146.0 (C6), 107.2 (C5), 93.84 (C1’), 
86.35 (C4’), 77.96 (C2’), 74.97 (C3’), 69.01 (C5’), 42.62 (CH2), 34.76 (CH2), 32.74 (CH3); ESI-
MS [M+Na]
+
: Calcd. for C14H18N2O8Na : 364.3, found : 364.0. 
 
5’-O-levulinyl 2’-O-monomethoxytrityl ribouridine (2.22) and 5’-O-levulinyl 3’-O-
monomethoxytrityl ribouridine (2.23): A tritylation reaction was conducted using nucleoside 
2.21 (2.0 g, 5.8 mmol), monomethoxytrityl chloride, MMT-Cl (2.4 g, 7.77 mmol) and silver 
nitrate (1.39 g, 4.50 mmol) which were dried under vacuum overnight before dissolving the 
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reagents in pyridine (6.0 mL) under nitrogen at room temperature (22 °C). The reaction was run 
for 3 h and tracked by TLC (95:5 CHCl3:MeOH) which confirmed the presence of the 2’ and 3’-
OMMT regioisomers, Rf (2.22): 0.40 and Rf (2.23): 0.28, respectively. The reaction mixture was 
then diluted with ethyl acetate (EtOAc) (60 mL) and washed twice with saturated sodium 
bicarbonate (NaHCO3) (60 mL). The organic layer was separated and dried using anhydrous 
sodium sulfate (Na2SO4). The solvent was evaporated and the crude product purified by silica gel 
column chromatography (96.5:2.5:1 chloroform:methanol:pyridine). The presences of pyridine 
in the elution buffer complicated the spotting on TLC, so a TLC plate pre-stained with 10% 
sulfuric acid in methanol was used to detect the product by detritylating the yellow colored 
MMT+ group. The 5’-O-levulinyl 2’-O-monomethoxytrityl ribouridine, 2.22, eluted first and 
was dried as a white foam in yields of 40%. The 5’-O-levulinyl 3’-O-monomethoxytrityl 
ribouridine, 2.23, eluted second and was dried to a white foam in yields of 20%. The identity of 
the 2’ and 3’-OMMT regioisomers was confirmed by 1H-1H COSY NMR which indicated a 
correlation cross-peak between the 3’H and 3’-OH in 2.22 and the 2’H and 2’-OH in 2.23. 
1
H NMR (2.22, 500 MHz, DMSO-d6):  11.29 (1H, s, NH), 7.49-6.77 (14H, m, MMT), 7.12 
(1H, d, J = 8.5 Hz, H6), 5.91 (1H, d, J = 7 Hz, H1’), 5.43 (1H, dd, J = 8 Hz, H5), 5.18 (1H, d, J = 
6 Hz, 3’OH), 4.21 (1H, dd, J = 6.5 Hz, H2’), 4.0 (2H, m, H5’), 3.87 (1H, dd, J = 11.75 Hz, H4’), 
3.71 (3H, s, OMe), 3.03 (1H, ddd, J = 1, 4.3, 7 Hz, H3’), 2.68 (2H, t, J = 6.3 Hz, Lv CH2), 2.37 
(2H, ddd, J = 7.5 Hz, Lv CH2), 2.08 (3H, s, CH3); 
13
C NMR (2.22, 125 MHz, DMSO-d6): 
207.3 (Lv CO), 172.4 (Lv CO), 163.4 (C2, CO), 158.9 (C4, CO), 150.9-123.3 (MMT, 19C), 
102.9 (C1’), 87.77 (C2’), 82.73 (C3’), 87.29 (C4’), 75.02 (C5’), 70.09 (OMe), 55.42 (CH2), 
37.76 (CH2), 29.97 (CH3); ESI-MS [M+Na]
+
: Calcd. for C34H34N2O9Na : 635.6, found : 635.6. 
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1
H NMR (2.23, 500 MHz, DMSO-d6):  9.57 (1H, s, NH), 7.60-6.70 (14H, m, MMT), 6.85 (1H, 
d, J = 7.5 Hz, H6), 5.86 (1H, s, H1’), 5.18 (1H, d, J = 7.5 Hz, H5), 5.29 (1H, s, 2’OH), 4.30 (1H, 
s, H2’), 4.13 (2H, d, J = 12.5 Hz, H5’, 5”), 3.98 (1H, s, H4’), 3.78 (3H, s, OMe), 3.48 (1H, s, 
H3’), 2.70 (2H, m, CH2), 2.41 (2H, m, CH2), 2.15 (3H, s, CH3); 
13
C NMR (2.23, 125 MHz, 
CDCl3-d1): 207.7 (CO), 172.4 (CO), 163.4 (CO), 159.0 (CO),, 151.5-127.6 (MMT, 19C), 113.5 
(C1’), 102.6 (C2’), 91.86 (C5) ,88.21 (C3’), 80.89 (C4’), 74.23 (C5’), 72.39 (OMe), 55.31 
(CH2), 37.79 (CH2), 29.70 (CH3); ESI-MS [M+Na]
+
: Calcd. for C34H34N2O9Na : 635.6, found : 
635.6. 
 
5’-O-levulinyl 2’-O-monomethoxytrityl 3’-O-phosphoramidous ribouridine (2.16) and 5’-O-
levulinyl 3’-O-monomethoxytrityl 2’-O-phosphoramidous ribouridine (2.24): Each purified, 
tritylated nucleoside was reacted separately in a phosphitylation reaction by first drying the 
tritylated nucleoside (1.05 g, 1.70 mmol) overnight prior to reaction. Dry tetrahydrofuran (THF) 
(15 mL) was added to the nucleoside under a flow of nitrogen and N,N-diisopropylethylamine 
(DIPEA) (1.26 mL, 9.70 mmol) and the phosphitylating reagent, Cl-P(OCEt)N(i-Pr)2 (700 µL, 
2.95 mmol) was to the flask. The reaction was stirred for 3 h at room temperature and monitored 
by TLC (2:1 Hexanes:Ethyl Acetate) until the formation of the phospharmadite diastereomers 
were observed, Rf (2.16): 0.50 and Rf (2.24) 0.50. A white precipitate, Cl
-+
NE(Et)(iPr)2, was also 
observed as an indication of reaction completion. Upon reaction completion, EtOAc (60 mL) 
was added to the reaction mixture prior to washing twice with saturated NaHCO3 (30 mL). The 
organic phase was dried over Na2SO4 and concentrated to a yellowish foam. The crude product 
was purified by silica gel chromatography (Hex:EtOAc, 2:1).  Products 2.16 and 2.24 were 
collected, dried as a white foam in yields of 55% and 60%, respectively.  
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31
P NMR (2.16, 80 MHz, CD3OD-d4):  152.2 and 148.5; ESI-MS [M+Na]
+
: Calcd. for 
C43H51N4O10PNa : 837.9, found : 837.4. 
31
P NMR (2.24, 80 MHz, CD3OD-d4):  152.4 and 149.6; ESI-MS [M+Na]
+
: Calcd. for 
C43H51N4O10PNa : 837.9, found : 837.4. 
 
2.7.3  SOLID PHASE RNA SYNTHESIS  
RNA was synthesized on an automated ABI 3400 synthesizer. Reagents for the synthesis 
cycle were as follows: detritylation reagent (3% solution of dichloroacetic acid in 
dichloromethane), coupling reagent (0.25 M ethylthiotetrazole in acetonitrile), capping reagent 
(Cap A: 1:1:8 v/v/v acetic anhydride:pyridine:tetrahydrofuran, Cap B: 16% N-methyl imidazole 
in tetrahdrofuran), oxidation reagent (0.02 M iodine in 75:20:5 v/v/v 
tetrahydrofuran:pyridine:water) and acetonitrile wash (Biotech grade purchased from EMI). 
Oligonucleotide syntheses were performed on a 1 µmol scale using 500 - 2000 Å LCAA CPG. 
RNA phosphoramidites were prepared as 0.2 M solutions in anhydrous acetonitrile with coupling 
times of 3 min. For the synthesis of branch RNA, the branchpoint phosphoramidites (2.16 or 
2.24) were also prepared as 0.2 M solutions in MeCN and coupled with an extended reaction 
time of 15 min. 
RNA syntheses were performed using the following synthesis cycle: Detritylation: 
Dichloromethane wash (40 sec) followed by delivery of 3% dichloroacetic acid in 
dichloromethane (90 sec total) split into pulsated 60 sec, then 30 sec, Coupling: delivery of RNA 
phosphoramidites with activator (0.25 M ethylthiotetrazole in acetonitrile), Capping:, delivery of 
Cap A and Cap B (12 sec) and Oxidation: delivery of oxidizing solution (0.02 M iodine in 
75:20:5 v/v/v tetrahydrofuran:pyridine:water) for 14 sec followed by a wait period of 20 sec. 
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Single stranded RNA sequences were extended in the 3’5’ orientation on solid-phase until 
completion.  
Branch and hyperbranch siRNA sequences (4-7, 14-17) and (8-11) were first grown in 
the 3’5’ position followed by coupling of the branchpoint phosphoramidite (2.16) and (2.24) 
respectively. The branchpoint phosphoramidite was coupled for 15 min, followed by a manual 
decyanoethylation step (2:3 v/v triethylamine:acetonitrile, 90 min) prior to the 2’-OMMT 
detritylation. The oligonucleotide bound CPG was washed with acetonitrile (30 mL) and 
replaced on the synthesizer to complete 3’5’ RNA synthesis of the antiparallel complimentary 
strand. The terminal 5’-OH was then capped with automated delivery of Cap A and Cap B (12 
sec). Following siRNA synthesis, the 5’-levulinyl protecting group was removed by flushing the 
column with 0.5 M hydrazine hydrate buffered in 3:2 v/v pyridine:acetic acid (20 min). 
Following delevulination, the CPG-bound 4, 8, and 14 are cleaved and deprotected from the 
solid support for analysis and purification. For constructs (5-7, 9-11, 15-17) automated branch 
RNA synthesis was continued from the branchpoint 5’-OH. For hyperbranch sequences (6, 7, 10, 
11, 16 and 17) an additional branch point phosphoramidite was coupled to the support-bound 
branch siRNA (5), and continued as previously described. In the case of hyperbranch siRNAs (6, 
7, 10, 11, 16 and 17) reverse RNA phosphoramidites (Chemgenes Inc.) were incorporated to 
maintain the antiparallel duplex siRNA orientation. 
 
2.7.4 CLEAVAGE AND DEPROTECTION OF RNA  
Cleavage and deprotection of the synthesized RNA was performed after drying the 
synthesizer columns under Ar(g) for 10 min. CPG-bound RNA was then transferred into 
autoclaved screw-cap microtubes (1.5 mL) and treated with a 1 mL solution of 1:1 v/v 
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ammonium hydroxide/methylamine (AMA) (for UltraFast TBDMS RNA phosphoramidites, 
Glen Research Inc.) deprotection and heated at 65 °C for 10 min or standard RNA TBDMS 
phosphoramidites were treated with 3:1 v/v ammonium hydroxide in absolute ethanol at 55 
o
C 
for 16 to 20 hours. RNA samples were then evaporated in-vacuo and the CPG was washed twice 
with autoclaved distilled water (500 µL). Crude oligonucleotides were re-suspended in a mixture 
of 1:1 v/v dimethylsulfoxide:triethylamine trihydrofluoride (125 µL) to complete the 2’-
desilylation reaction at 65 °C for 90 min. The crude RNA samples were subsequently 
precipitated from the reaction mixture with 3 M NaOAc (25 µL) in n-BuOH (1 mL). 
Precipitation was completed on dry ice for 1 h prior to centrifugation (12 000 rpm) leaving the 
crude oligonucleotides as a solid white pellet. For DMT-ON RNA purification, immediately after 
desilylation, samples were cooled to room temperature followed by addition of 1.75 mL of 
quenching buffer (Glen Research Inc). The quenched RNA samples were transferred to Glen-Pak 
RNA cartridges and purified according to the manufacturer’s protocol. The collected RNA 
samples were dried in a Speedvac concentrator and re-suspended in autoclaved water (1 mL) for 
yield determination using UV absorbance measurements at 260 nm.  
 
2.7.5 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE)  
siRNA samples (1-17) were analyzed using denaturing PAGE. Analytical samples were 
prepared by drying 0.1 OD (A260) overnight and re-suspending the sample in a denaturing 
formamide solution (80% formamide in 10X TBE buffer) prior to loading on the gel. Samples 
were loaded (20 µL/well) along with dye solution (5 µL of 10 mL formamide mixed with trace 
amounts of bromophenol blue and xylene cyanol) to track gel migration. The gels were run at 
500 V in 1X TBE running buffer on a 7 M urea (21 g), 18% polyacrylamide gel (acrylamide and 
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N,N-methylene bisacrylamide, 22.5 mL), prepared using 10x TBE buffer solution (5 mL) 
[tris(hydroxymethyl)aminomethane (TRIS) (54.5 g), boric acid (27.8 g) and 
ethylenediaminetetracetic acid (EDTA) (1.86 g) in autoclaved water (500 mL), pH 8] for 2 -3 
hours. Gels were visualized under short range (265 nm) UV-shadowing and subsequently placed 
in a Stains-All
®
 (Sigma) solution (25 mg Stains-All
®
, 50 mL isopropyl alcohol, 25 mL 
formamide, 125 mL water). After 2 h, the gel was removed from the stain solution and exposed 
to light for analyses. 
For purification, branch and hyperbranch samples (4-7) were prepared using >6.0 OD (A260). 
Samples were loaded with formamide (150 µL) and run at 500 V in 1X TBE running buffer until 
completion (2 -3 h). Desired product bands were excised from gel and incubated in 1 mL of 
autoclaved water overnight at 22 °C to complete the extraction of RNA from the gel. RNA was 
desalted using NAP-10 Sephadex G-25 (Illustra™) according to the manufacture’s protocol and 
quantified using UV-Vis spectroscopy at 260 nm. 
Pure siRNAs (1-17) were analyzed by native PAGE. Samples were prepared by hybridizing 
stoichiometric quantities (0.5 nmol) of complimentary single strands in 20 µL of 1X TAE buffer 
(40 mM Tris, 20 mM acetic acid, and 1 mM EDTA pH 8.0) and 5 µL of 30% sucrose solution in 
1X TAE buffer. Branch and hyperbranch oligonucleotide (0.1 – 0.2 µM) were directly dissolved 
in 30% sucrose loading buffer (30% sucrose in 5X TAE buffer).  All samples were heated at 95 
°C for 5 min cooled to room temperature over 1 h and stored at 4 °C overnight. A 18% native 
PAGE was prepared using 5 mL of 10X TBE buffer, 22.5 mL (acrylamide and N,N-methylene 
bisacrylamide) and 22.5 mL of autocalved water. Gel was run at 500 V for 2.5 h and visualized 
under UV shadowing at 260 nm. 
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2.7.6 ION PAIRING REVERSE PHASE HPLC (IP RP HPLC)  
All samples (1-17) were analyzed by IP RP HPLC to determine purity. HPLC was 
performed on a Waters
®
 2695 Alliance Separations Module. Crude samples were dissolved in 
autoclaved water (0.1 OD for analytical) and injected into a Waters Symmetry C-18 reverse 
phase column (4.6 x 150 mm, 5 µm particle size, 120 Å) using a gradient of 10-95% (20% 
acetonitrile in 0.1 M triethylammnonium acetate) at 60 
o
C with a flow rate of 1 mL/min over 23 
min at 260 nm. Peak areas were calculated to determine percent purity of samples. IP RP HPLC 
was used to confirm siRNA purities>90% following purification. 
 
2.7.7 MASS SPECTROMETRY 
siRNA samples (0.1-0.4 µM) were dissolved in autoclaved water and analyzed by mass 
spectrometry. Samples were analyzed by Dr. Mark Hail at Novatia LLC, Newton, PA, utilizing 
Oligo HTCS equipped ESI/MS in negative mode. The data was obtained and deconvoluted using 
ProMass software. Theoretical molecular weights were calculated by entering each sequence on 
IDT website OligoAnalyzer 3.1 or on Mongo and analyzing the sequence; 
http://www.idtdna.com/analyzer/Applications/OligoAnalyzer, or http://rna-
mdb.cas.albany.edu/RNAmods/rnamass.htm respectively. 
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CHAPTER 3. STRUCTURE AND BIOPHYSICAL STUDIES OF siRNAs  
3.1 ABSTRACT 
Methods for characterizing siRNA structure and biophysical properties are highlighted in this 
chapter. Specifically, Circular Dichroism (CD) spectroscopy was used to investigate siRNA 
secondary structure in physiological conditions. Linear, branch and hyperbranch siRNAs were 
all found to exhibit the putative A-type helix, which is the trademark RNA structure associated 
with double-stranded RNA sequences. Moreover, thermal denaturation experiments using UV-
Vis spectrophotometry were used to evaluate hybrid stability at 260 nm (% hyperchromicity) 
with changes in temperatures (5-90 
o
C). The melting temperatures at which 50% of the hybrids 
dissociates to single-strands (Tm) were used to evaluate the thermal stabilities of the siRNAs. 
Branch and hyperbranch siRNAs displayed stable hybrid structures (Tm: 68 - >90 
o
C) relative to 
the linear controls (Tm: 67 - 76 
o
C), and in some cases were found to contain multiple hybrid-to-
single-strand transitions. These results were found to be consistent with stable unimolecular 
RNA hybrids, such as those associated with RNA hairpins and with more complex RNA 
structures which contain multiple complementary sequences that can denature at elevated 
temperatures. Moreover, the 2’-OMe siRNAs were found to display well defined A-type helical 
structures and stable thermal denaturation curves (Tm: >90 
o
C) relative to the native sequences. 
Thus, linear, branch and hyperbranch siRNAs were found to exhibit the pre-requisite hybrid 
structures and stabilities for triggering the RNAi response.  
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3.2 INTRODUCTION 
3.2.1 CD SPECTROSCOPY OF RNA 
 Circular Dichroism (CD) spectroscopy determines the effects of circularly polarized light 
on an asymmetric molecule.
1
 In this application, unpolarized light from a suitable source (e.g. 
Xenon arc lamp) is filtered by a monochromator which selects the wavelengths of interest, 
typically in the far UV-region (190 - 310 nm) for biomacromolecules, while minimizing stray 
light. The beam is then deflected by mirrors and prisms into a plane polarizer which focuses the 
light in the same direction before it passes through a photoelastic modulator. This circular 
polarizer produces left and right-handed circularly polarized light. The circularly polarized light 
then passes through the sample compartment where it interacts with the analyte and produces a 
CD signal (ellipticity) as a function wavelength (Figure 3.1). The interaction between 
chromophoric chiral molecules and circularly polarized light has been shown to provide 
important structural information of simple asymmetric molecules and more challenging 
macromolecules.
2 
Thus, any conformational change in an asymmetric molecule that can absorb 
light can be studied by CD spectroscopy. This technique is especially advantageous for the rapid 
structure determination of complex biomacromolecules such as proteins, DNA and RNA.
3
 This 
technique produces very sensitive and well resolved structural characteristics of biological 
molecules in dilute solutions (low M concentrations) which mimic physiological conditions, 
and thereby providing insight on its biologically active structure. Moreover, a CD analysis is a 
relative experiment, in which a CD spectrum of an unknown sample is typically compared with 
suitable controls to determine structural differences and similarities between samples. Therefore, 
CD spectroscopy is an ideal method for producing quick structural analyses of complex, 
biologically active molecules.  
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Figure 3.1. CD spectroscopy method and sample analysis.
2 
 
Nucleic acids own the ability to absorb circularly polarized light and emit a CD spectrum 
contingent on their conformations. This is due to the chiral sugar component and the aromatic 
nucleobases that absorbs light strongly in the UV region (260 nm: Ade = 15, 340, Cyt = 7,600, 
Gua = 12, 160, Ura = 10, 210) resulting in * transitions.4 In the case of single-stranded 
RNA, the CD spectrum depends on the chirality of the sugar-phosphate backbone and the 
absorption of the nucleobases, relating their stacking arrangement in solution.
 
For example, the 
CD spectrum of the dinucleotide ApA, originates from the chiral adenine-adenine interaction 
which projects a CD signature that contains a combination of positive and negative extrema at 
260 nm, referred to as exciton bands (Figure 3.2, i).
2,5
 In comparison, the CD spectrum for 
double-stranded RNA is strikingly distinct, featuring a maximum band near 260 nm, a minimum 
one near 210 nm and less intense exciton bands in between 290 – 310 nm (Figure 3.2, ii).2,6 This 
CD signature corresponds to A-type RNA, which is the canonical double-stranded RNA 
structural motif characterized as an anti-parallel, complementary, right-handed, helical duplex 
structure.
7
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Figure 3.2. CD Spectra of i. ApA dinucleotide vs. Adenosine and ii. A-type double-stranded 
RNA helix.
2 
 
The A-type RNA double-stranded helix is pre-organized by a nucleotide sugar pucker 
conformation which adopts a Northern or C3’-endo geometry.8 In this conformation, the C3’ and 
C5’ carbons lie above the median plane defined by C1’-O4’-C4’ such that the C5’-C3’-phosphate 
diester bond distance is reduced to 5.9 Å. This conformational restraint results in a more compact 
duplex conformation with 11 base pairs per helical turn and distances between base-pairs along 
the helix axis of 2.6 Å. Furthermore, the bases are displaced by 4.5 Å from the parallel helix axis 
creating a deep but narrow major groove and shallow but broad minor groove. This 
conformation is also stabilized by the O4’-O2’ anomeric effect and the gauche effects of the O2’-
C2’-C1’-O4’ torsion angles.8 These characteristics generate the geometric parameters found in A-
RNA duplexes (Figure 3.3).
9
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Figure 3.3. The global helical conformation of A-RNA and its preferred sugar conformation. 
Structures and data adapted from reference 9.  
 
Considering siRNA encompass a class of short (18-21 nucleotides) double-stranded 
RNA, CD spectroscopy is perfectly suitable for studying the structures of native and modified 
sequences. The A-form RNA geometry is a pre-requisite for siRNA binding to RISC and for 
stimulating RNAi activity. Moreover, the incorporation of modified nucleic acids have been 
shown to improve the pharmacokinetic properties of the siRNAs, while instilling more potent 
gene silencing effects. For example, the selective incorporation of 2’-OMe RNA was found to 
reduce toxic ‘off-target’ gene silencing effects.10 Meanwhile, the incorporation of 2’-deoxy-2’-
fluoro-4’-thioarabinouridine (4’-S-FAU) within siRNA was shown to maintain A-type RNA 
structure while triggering RNAi activity targeting the firefly luciferase gene.
11
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3.2.2 UV-VIS SPECTROSCOPY OF RNA 
 UV-Vis (absorption) spectroscopy measures the interaction of light in the near UV (190 – 
400 nm) to visible region (400 – 800 nm) with a suitable chromophore.12 The chromophore is 
typically a conjugated molecule (e.g. aromatic) owning the ability to absorb light and inducing 
an electronic transition from a ground to excited state (e.g. *). The absorption of light by 
the sample at a given wavelength produces an absorption spectrum. 
 UV-Vis spectrophotometers
12
 are equipped with two light sources, typically a deuterium 
lamp for the UV region and a tungsten-halogen lamp for the visible region. The light source 
passes through a monochromator which focuses the beam of light onto the sample. Based on the 
molar absorptivity of the sample, concentration of the solution and path length of the cell, light is 
absorbed (while some is transmitted) and detected by a photomultiplier or a photodiode detector. 
The UV-Vis (absorption) spectrum correlates the absorbance of the solute in a transparent 
solvent (e.g. buffer) at a given wavelength (Figure 3.4).  
 
Figure 3.4. Schematic of UV-Vis absorption spectrophotometer.  
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UV-Vis (absorption) spectroscopy can correlate the concentration of the sample in solution for 
quantitative measurements. Moreover, this method can also provide information on ligand-
binding interactions, conformational transitions and thermodynamic properties of complex 
biomacromolecules.
12
   
Absorption spectroscopy is particularly well suited for RNA analyses. This is due to the 
favorable absorptivities of the nucleobases in the far-UV (210-310 nm) region (260 nm: Ade = 15, 
340, Cyt = 7,600, Gua = 12, 160, Ura = 10, 210).
4 
This property facilitates the quantitative 
determination of RNA in solution.
12
 For example, the optical density (O.D.) measures the 
absorption of RNA at 260 nm (A260nm) in 1 mL of buffer and analyzed in a 1 cm path length 
cuvette. Stoichiometric measurements can be calculated using the Beer-Lambert law (equation 
3.1), which correlates the absorption of the RNA sample at 260 nm (A260nm) with its 
concentration (c, mol/L) in solution, the molar absorptivity of the RNA sequence (, Lmol-1cm-1) 
and the path length of the cuvette (l, cm).  
  
A260nm =  c l      equation 3.1 
 
 Changes in RNA secondary structures can also be monitored by absorption 
spectroscopy.
13-14
 For example, increases in UV absorptivities typically accompanies transitions 
from ordered RNA duplexes to random single-stranded forms. This change in hyperchromicity is 
associated with the ability for the RNA nucleobases to absorb light strongly as ‘open’ single-
strands vs. ‘closed’ hybrids.  Denaturing agents such as formamide, urea and heat have all been 
applied to disrupt the Watson-Crick hydrogen bonding interactions between the complementary 
strands. The ability to resists hybrid denaturation provides a measurement of hybrid stability. 
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This is the case with thermal denaturation experiments, which monitors the % changes in 
hyperchromicities at 260 nm with increasing temperatures.
13
 The melting curve describes a phase 
transition for the melting of a duplex to single-stranded form (Figure 3.5). The midpoint of this 
curve provides the melting temperature (Tm, 
o
C) at which 50% of the RNA duplex has denatured 
to single-stranded form (helix-coil transition). Basically, the higher the melting temperature the 
more stable the hybrid structure.  
  
Figure 3.5. Typical melting curve displaying the phase transition from helix-coil at 260 nm with 
increasing temperatures.
14 
  
 
Since RNA hybrid thermal stability can be determined from the melting curves, this 
experiment may also lead to a thorough thermodynamic analysis of the folded RNA structure.
14
   
RNA thermal denaturation thus provides the basis for calculating thermodynamic data associated 
with this energy driven process. These include: standard free energy changes in hybrid stability 
(ΔGo), enthalpy measuring the heat changes during the temperature dependent thermal melt 
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(ΔHo) and the entropy gain (ΔSo) during the helix-to-coil transition. These calculations are 
thoroughly reviewed elsewhere
14
, and will not be further discussed in this study.  
Stable siRNA hybrids and related analogs have been shown to trigger potent gene 
silencing effects. This is especially the case with the site specific incorporations of 2’-OMe RNA 
within bio-active siRNA sequences. 2’-OMe RNA stabilizes the requisite C3’-endo sugar pucker 
in an A-type helical arrangement due to favorable anomeric and gauche interactions (Figure 
3.6).
8,15
 This effect has been shown to produce effective GRP78 silencing siRNA in HeLa cells.
16
 
Moreover, the 2’-OMe RNA modifications were also found to increase siRNA metabolic 
stability leading to extended RNAi activity, while minimizing the silencing of unintended gene 
targets which diminishes toxicity.
10,16
 The latter is a focal point of our study, which aims to 
develop potent GRP78 siRNAs for applications in cancer-targeting gene therapy (Chapter 4).  
  
  
Figure 3.6. Structure and conformation of 2’-OMe RNA 
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3.3 CHAPTER OBJECTIVES 
The bio-physical and structural studies of linear, branch and hyperbranch siRNAs will be 
reported in this chapter. These studies are essential in determining the pre-requisite siRNA 
structure for biological activity. In the RNAi pathway, the RNA-Induced Silencing Complex 
(RISC) recognizes and binds to an A-type double-stranded RNA helix. This structure has been 
found to be the bio-active conformation for high affinity and selective RNA substrate binding to 
the active site of RISC.
17
 Moreover, this protein complex also contains enzymatic activity 
associated with RNA hydrolysis.
18
 Thus, A-form siRNA structure and duplex stability are 
necessary requirements for RISC recognition and mRNA cleavage activity in order to stimulate 
potent gene silencing effects in vivo. In this chapter a variety of siRNA sequences and motifs 
targeting GRP78 mRNA will be studied using CD spectroscopy (structure analyses) and UV-Vis 
thermal denaturation (hybrid stability) in order to elucidate their suitability for RNAi application 
(Chapter 4).  
 
3.4 RESULTS AND DISCUSSION 
3.4.1 CD SPECTROSCOPY OF siRNAs 
In order to assess whether the siRNAs described in Chapter 2 of this thesis (Table 2.1, 
sequences 1-17) adopt the pre-requisite A-type duplex for RNAi activity, CD spectroscopy
1-6
 
was used to determine their secondary structures relative to single strand controls (Figure 3.7). 
Briefly, siRNA samples were prepared by annealing complementary sequences in a 
physiologically relevant phosphate buffer (50 µM, 140 mM KCl, 1.0 mM MgCl2, 5.0 mM 
Na2HPO4, pH 7.2) prior to structural analyses by CD spectroscopy. Linear GRP78 siRNA
16
 
demonstrated typical CD profiles for A-form helices, displaying small minimum bands at 210 
88 
 
and 240 nm in addition to a broad maximum between 255-290 nm (Figure 3.7, c, d).
6 
These 
characteristic signatures in the CD spectrum were distinct from the single-strand controls 
(Figure 3.7, a, b), which were found to display random coils with weak exciton bands at around 
260 nm corresponding to the absorptivities of the nucleobases.
2
 In the case of the branch and 
hyperbranch sequences (Figure 3.7, e-g), the A-type broad maximum and minimum bands were 
also observed between 255-290 nm and at 210, 240 nm, respectively, albeit with a decrease in 
the amplitudes of molar ellipticities at these characteristic wavelengths. This suggests some of 
the branch hybrids may contain varying proportions of random coil. This is not entirely 
surprising, considering the branchpoint nucleotide has been found to slightly distort duplex 
structure by restricting the complementary strands within a single molecular structure.
9 
Nevertheless, branch oligonucleotides were found to maintain their putative geometry for 
triggering biological activity.
9,19
  In this case, the branch siRNAs composed  of the un-natural 
2’,5’- and vicinal 3’,3’-phosphodiesster linkages were found to be particularly un-stable, leading 
the hydrolysis of the branchpoint linkages and release of the single strands (Figure 3.7, f).
9
 In 
spite of this change, branch and hyperbranch sequences generally maintained  CD signatures that 
were consistent with the canonical A-like helical structures. Thermal denaturation experiments 
were next conducted to determine the thermal stabilities of the duplex structures.   
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Figure 3.7. CD spectroscopy of the siRNA sequences described in this study (Table 2.1). 
 
3.4.2 UV-VIS SPECTROSCOPY OF siRNAs 
      In order to assess the duplex stabilities of the branch and hyperbranch siRNAs relative 
to their linear controls, thermal denaturation experiments were conducted. The siRNAs (Table 
2.1, sequences 1-17, 0.10 - 0.40 µM) were prepared as previously described for the CD studies, 
by annealing samples in physiological phosphate buffer (140 mM KCl, 1 mM MgCl2, 5 mM 
Na2HPO4, pH 7.2) followed by the bio-physical studies using UV-Vis spectroscopy
12-14
 (Figure 
3.8). Linear single stranded RNAs had little or no hyperchromic shifts in the Tm studies (Figure 
3.8, a, b). However, once annealed, linear siRNA sequences 1-3, gave characteristic thermal 
denaturation curves that were consistent with a helix-to-coil transitions, (Tm: 67 – 72 
0
C, Figure 
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3.8, c). Site specific incorporation of 2’-OMe RNA within the native siRNA sequences 1 and 2, 
produced more stable hybrids (ΔTm: +1 and +5 
o
C, for 12 and 13, respectively) with consistent 
changes in hyperchromicities (ΔH: 25-30%) during thermal denaturation (Figure 3.8, c and d). 
Branch and hyperbranch sequences, 4-7, exhibited broad thermal denaturation curves suggesting 
multiple helix-to-coil transitions (Figure 3.8, e). These results are consistent with those 
associated with more complex RNA motifs, from which each helix-to-coil transition may be 
measured at a distinct Tm value.
20
 Moreover, the branch and hyperbranch siRNAs, 4-7, displayed 
greater thermal stabilities (Tm: 68 – 89 
o
C) and enhanced hyperchromicities (%H: 5-35 %) 
relative to their linear controls (Tm: 67 - 72 
o
C and %H: 5-25%). Considering that structurally 
related RNA hairpins possess thermodynamically more stable folded structures relative to their 
linear double-stranded sequences, the enhanced hybrid stabilities observed for the branch 
siRNAs was not unexpected.
21
  Consistent with the CD data, the branch siRNAs composed of the 
un-natural 2’,5’- and vicinal 3’,3’-phosphodiesster linkages were found to be particularly un-
stable, leading to broad Tm curves that were reminiscent of the linear single strand controls 
(Figure 3.8, a and f). Whereas the branch siRNAs composed of the 2’-OMe RNA inserts, 14-17, 
(Tm: 75 – 77 and >90 
o
C, Figure 3.8, g) were found to produce more stable hybrids when 
compared to the native branch sequences, 4-7, (Tm: 69 – 89 
o
C, Figure 3.8, e). This was found to 
correlate with literature precedence, which reports that 2’-OMe RNA stabilizes the requisite C3’-
endo sugar pucker in an A-type helical arrangement due to favorable anomeric and gauche 
interactions (Figure 3.6).
8,15
 These results are also in agreement with the native polyacrylamide 
gel electrophoresis (Figure 2.15) and CD spectroscopy (Figure 3.7) data which displayed stable, 
higher ordered A-type helical structures for the branch and hyperbranch sequences in comparison 
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to the linear double stranded siRNA controls. In light of their enhanced duplex stabilities and A-
type helices, branch and hyperbranch siRNAs were next evaluated for RNAi activity (Chapter 4). 
 
 
Figure 3.8. Thermal denaturation curves of the siRNA sequences described in this study (Table 
2.1). 
 
 
3.5 CONCLUSIONS 
In this chapter, siRNA structure and biophysical properties have been validated. CD 
spectroscopy was used to confirm the A-type helical geometry for the siRNAs in physiological 
buffer. Moreover, thermal denaturation experiments using UV-Vis spectrophotometry revealed 
the melting temperatures (Tm) of the siRNAs at 260 nm. In general, branch and hyperbranch 
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siRNAs displayed stable hybrid structures (Tm: 68 - >90 
o
C) relative to the linear controls (Tm: 67 
- 76 
o
C). These results were found to be consistent with those associated with RNA hairpins that 
can form stable hybrids from a single molecular structure. Interestingly, short hairpin RNA 
(shRNA) have also been implicated in the RNAi response leading to potent gene silencing 
effects.
22
 Moreover, the 2’-OMe siRNAs were found to display well defined A-type helical 
structures and stable thermal denaturation curves (Tm: >90 
o
C) relative to the native sequences. 
This highlights their potential utility in stabilizing the canonical siRNA structure for RNAi 
activity.
10, 16
 Exceptionally, the branch siRNAs encompassing the labile 2’,5’- and 3’,3’-
phosphodiester bonds at the branchpoint positions were found to produce unstable hybrids 
according to the CD and thermal denaturation data. Thus, linear, branch and hyperbranch 
siRNAs were found to generally display the pre-requisite hybrid structures and stabilities for 
triggering the RNAi response. The biological activity of the siRNAs synthesized in this study 
(Table 2.1, sequences 1-17) will be highlighted in Chapter 4.   
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3.7 EXPERIMENTAL SECTION 
3.7.1 UV-VIS SPECTROSCOPY 
siRNAs (0.1 - 0.5 µM, Table 2.1 sequences 1-17) were annealed in physiological phosphate 
buffer (1.0 mL, 140 mM KCl, 1.0 mM MgCl2, 5.0 mM Na2HPO4, pH 7.2) and heated at 95 °C 
for 5 min and allowed to cool to room temperature for 1 h and stored at 4 °C overnight prior to 
thermal denaturation experiments. Complementary siRNA strands were measured on a CARY 
3E, UV-Vis spectrophotometer equipped with a temperature controller monitoring the changes in 
hyperchromicities at 260 nm with increasing temperatures (5-95 
o
C at 0.5 °C/min). Nitrogen was 
used to prevent condensation at lower temperatures (<20 
o
C). The melting temperature (Tm) was 
calculated from the first derivative plots of the melting curves, representing the temperature at 
which 50% of the duplex has denatured to the corresponding single strands. This data was 
exported into an Excel™ spreadsheet for plotting the Tm curves. 
3.7.2 CD SPECTROSCOPY 
Samples were prepared in similar fashion to the Tm experiments, briefly, siRNAs (0.10 - 0.50 
µM, Table 2.1 sequences 1-17) in physiological phosphate buffer, 140 mM KCl, 1.0 mM 
MgCl2, 5.0 mM Na2HPO4 pH 7.2. Annealed siRNAs were transferred to fused quartz cells with a 
1 cm path length and maintained within the cell holder at 10 °C under N2 for 10 minutes prior to 
spectral acquisition. Spectra were collected using a Laurier AVIV 62A DS CD 
spectrophotometer as an average of 3 scans with a 1.0 nm band width interval and a 0.5 nm step 
interval. Spectra were analyzed between 210 and 310 nm and raw data was processed using J-
700 Windows® software (version 1.00) and correcting by subtracting the buffer followed by 
smoothing the data points. The data was then exported into Windows Excel™ spreadsheet 
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software for plotting the CD spectra as changes in molar ellipticities with increasing 
wavelengths. 
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CHAPTER 4. RNAi ACTIVITY OF GRP78 TARGETING siRNAs 
 
4.1 ABSTRACT 
Following successful synthesis, structural and biophysical characterization, the biological 
activity of linear, branch and hyperbranch siRNAs is described in this chapter. More specifically, 
GRP78 targeting siRNAs were applied for silencing GRP78 mRNA and triggering cancer cell 
death within HepG2 hepatoblastoma cells. GRP78 has been classified as a valid molecular target 
in cancer therapy due to its implications in cancer initiation, proliferation, metastatic spread and 
resistance towards chemotherapeutics. Thus, inhibiting GRP78 function in resilient cancer cell 
lines (e.g. HepG2 cancer cells) may serve as an ideal method for overcoming tumor resistance, 
thereby providing a breakthrough in the development of more effective anti-cancer treatment 
methods. Towards this goal, Lipofectamine™ 2000 was used as the benchmark siRNA cell 
delivery (i.e. transfection) reagent in quantities (< 7 g) that did not compromise HepG2 cell 
viability. In complex with siRNAs (40 - 80 pmol), potent GRP78 silencing (50 - 70%) was 
observed by confocal laser scanning microscopy and western blotting. The branch and 
hyperbranch siRNAs (Table 2.1, sequences 4-7) were found to trigger significant GRP78 
knockdown (50 - 70%), illustrating their potential as new substrates for silencing oncogene 
expression. In spite of their potent GRP78 silencing effects in HepG2 hepatoblastomas, only 
modest cancer cell deaths (< 20%) were observed following siRNA treatment (20-80 pmol, 48-
96 h). These results confirm the suitability of the novel branch and hyperbranch siRNAs in the 
RNAi application, but also highlights the resiliency of the HepG2 cells towards GRP78 
knockdown. This discovery is not only important to the development of new gene therapy 
applications, but also for screening new gene targets that may be implicated in cancer resistance.  
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4.2 INTRODUCTION 
4.2.1 SELECTION OF GRP78 AS A MOLECULAR TARGET IN CANCER THERAPY 
The Glucose Regulated Protein 78 (GRP78) was originally identified from tissue culture 
grown in the absence of glucose and resulting in the overexpression of a 78 kilodalton protein.
1
 
GRP78 is also referred to as Bip, due to its ability to bind to the immunoglobulin heavy chains 
on pre-B cells.
2
 GRP78 has since then been characterized as a member of the heat shock family 
of chaperone proteins (HSP70), primarily assisting in protein folding events in the lumen of the 
endoplasmic reticulum (ER).
3
 GRP78 activity is stimulated in the presence of physiological ER 
stress signaling, typically associated with cell aging, intracellular Ca
2+
 efflux, glucose 
deprivation, hypoxia and the accumulation of misfolded proteins. These signaling pathways have 
been extensively reviewed elsewhere
4,8
, and only a cursory review of GRP78 activity associated 
with physiological ER stress signaling will be described herein. In the case of protein misfolding, 
the unfolded protein response (UPR) is activated, inhibiting the biosynthesis of additional 
proteins and stimulating the activity of chaperone proteins such as GRP78 to assist in protein 
folding events.
4
 In this mechanism, ER stress signaling stimulates the release of free form 
GRP78 from protein kinase like ER kinase (PERK), inositol requiring enzyme 1 (IRE1) and 
activating transcription factor 6 (ATF6) to unleash the UPR signaling pathway (Figure 4.1).
4
 
This results in PERK-catalyzed phosphorylation of the eukaryotic initiation factor 2 alpha 
(eIF2), preventing the translocation of additional proteins in the ER.5 Dimerization of IRE1 
stimulates its endoribonuclease activity which splices XPB1 mRNA leading to the expression of 
a basic leucine zipper family of transcription factors that assist in the production of chaperone 
proteins.
5
 Similarly, ATF6 is transported to the Golgi where it is cleaved and activated to a 
functional transcription factor that aids in the expression of chaperone genes that assists in 
protein folding events as part of the UPR signaling pathway.
6
 In this manner, the UPR functions 
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to elevate GRP78 expression levels and activity to release the ER biosynthetic burden in stressed 
cells, while allowing them to maintain their functionality for cell survival. Thus, GRP78 
functions to inhibit cell apoptosis by rescuing the accumulation of unfolded proteins that may 
compromise cell activity, suppress the formation of reactive oxygen species during hypoxia, and 
by interfering with caspase activation and caspase mediated cell death.
7
  
 
Figure 4.1. The many roles of GRP78 in the UPR signaling pathway associated with ER stress. 
Figure redrawn from reference 4c. 
 
Moreover, electron microscopy has demonstrated that GRP78 is secreted from the ER to 
a variety of intracellular organelles for widespread biological activity (Figure 4.2).
8
 For 
example, GRP78 activity in the perinuclear portion of the ER is also associated with preserving 
intracellular Ca
2+
 homeostasis.  In this manner, GRP78 regulates Ca
2+ 
efflux from the ER to the 
mitochondria where it functions to stimulate oxidative metabolism for cellular bioenergetics and 
survival.
9
 GRP78 expression and activity have also been observed in the nucleus of the cell, 
where it is speculated to play a pivotal role against DNA-damage induced apoptosis.
10
 Cytosolic 
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GRP78 functions to regulate UPR signaling associated with the protein misfolding response, 
viral protein assembly and minimizing lead neurotoxicity.
11
 Interestingly, under ER stress or 
pathological conditions, GRP78 is translocated from the ER to the plasma membrane. As such, 
cell surface GRP78 has been characterized on rapidly proliferating endothelial, monocytic cells 
and tumors, where it behaves as a signaling receptor for cell survival.
12
 A certain fraction of cell 
surface GRP78 may also be secreted extracellularly, where anti-GRP78 antibodies are produced 
and can be isolated from the serum.
13
 The antibodies which bind to the N-terminal domain of 
GRP78 have been shown to stimulate cell proliferation and protection against apoptotic events. 
Conversely, the selection of C-terminal GRP78 antibodies has been shown to trigger apoptosis. 
  
 
Figure 4.2. GRP78 cellular localizations and activities. Redrawn from reference 8. 
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 The cell surface localization of GRP78 in selected cell types associate’s with 
physiological stress conditions such as with hypoxia or glucose deprivation and pathological 
disorders such as in cancer and metabolic diseases makes GRP78 a potential molecular target for 
therapeutic applications. In cancer, cell surface GRP78 signals initiation, proliferation, 
metastasis, resistance towards chemotherapy and radiation treatments (Figure 4.3).
4,8,14
  
 
Figure 4.3. Pluripotent cancer cell surface GRP78 signaling. Redrawn from reference 8. 
 
Although these signaling pathways are extensively described elsewhere
4,8,14
, a cursory 
review is provided in this section to highlight the relevance of GRP78 signaling on 
tumorigenesis. In 1-LN prostate cancer cells, GRP78 has been found to act as a receptor for 
activated 2-macroglobulin binding which signals the activation of p-21 activated kinase-2 
(PAK-2), LIM domain kinase 1 (LIMK1) and cofilin phosphorylation that subsequently 
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promotes tumor metastatic spread.
15
 Moreover, the GRP78-2-macroglobulin binding 
interaction also triggers cell survival and proliferation in solid tumors via the AKT and NF-KB 
signaling cascade which is activated by phosphorylation with intracellular kinases (e.g. ERK 1/2, 
MAPK, Akt, PI3K).
16
 Cripto, a multifunctional cell surface protein also binds to cell surface 
GRP78, enhancing tumor growth by inhibiting transforming growth factor- (TGF-) signaling 
activity.
17 
Moreover, Kringle 5 and Par-4 have also been identified as GRP78 cell surface 
binding partners that increase intracellular apoptotic events. The ability for GRP78 to block 
apoptosis includes its binding and inactivation of CHOP, BIK and caspase 7, cell death effector 
proteins.
18
 Additionally, GRP78 chemoresistance has been hypothesized by the synergistic 
effects of the pro-survival UPR mechanism and cell proliferative effects of the AKT/PI3K 
signaling pathway.
19
 Thus, GRP78 signaling pluripotency enables tumor cell survival and 
progression by evading the cell death response or depending on protein partner, increases 
apoptosis. 
Cell surface GRP78 signaling activity and overexpression have been correlated with a 
variety of solid tumors of the urinary, lymphatic, digestive, mammary, cerebral and respiratory 
systems, but not in normal tissues (Figure 4.4).
4,8,14
 For example, the GRP78 
immunohistochemical reactivity was found to be significantly higher in prostate cancer and 
lymph node metastasis specimens when compared to corresponding benign tissue controls.
20
 
GRP78 levels were also found to be markedly higher in human renal carcinoma
21
 and in gastric 
cancer
22
 specimens relative to the adjacent non-tumor tissues. Overexpression of GRP78 in 
hepatocellular carcinoma promoted tumor invasion in vitro and in vivo due to the activation and 
activity of a focal adhesion kinase (FAK) which negatively regulated Rock kinase activity by 
promoting the phosphorylation of p190RhoGAP.
23 
In breast cancer, GRP78 has been found to 
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correlate with metastatic spread and resistance towards chemotherapeutic treatments such as 
adriamycin, etoposide, taxol and vinblastine.
24
 The overexpression of GRP78 has also been 
found in brain tumors associated with malignant glioma tissues (Figure 4.4). In these cases, 
GRP78 activity has been correlated with resistance to chemotherapy and -radiation, induction of 
tumor proliferation and a low median survival rate for the patients.
25
 The same trend has also 
been observed in lung
26
 and melanoma
27
 tumors, making GRP78 a ubiquitous tumor biomarker 
for the development of targeted anti-cancer approaches.  
 
 
Figure 4.4. Immunohistochemical staining of GRP78 in human glioma tissues and normal brain. 
The two cross-sections of peritumoral brain tissues were stained with anti-GRP78 antibody (red) 
and blue hematoxylin as background stain.
25 
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Inhibitors of GRP78 activity have been shown to trigger apoptosis in cancer cells (Figure 
4.5). For example, epigallocatechin gallate, (4.1, EGCG), a flavonoid natural product found in 
green tea leaves and honokiol, (4.2, HNK), a magnolia grandiflora derivative have been shown to 
bind to the GRP78 ATPase domain, induce ER stress leading to potent cell death effects in 
melanoma, glioblastoma and neuroblastoma cell lines with and without ER stress inducers 
fenretinide or bortezomib.
28  
In a structure-design based approach, a library of synthetic 
adenosine-based inhibitors, targeting the GRP78 ATP binding domain were developed for 
structure-activity relationship studies.
29
 The lead analog, 4.3, retained potent (KD: 60 nM) and 
selective GRP78 binding affinity when screened against homologous heat shock proteins. 
Verrucosidin (4.4, VCD) a fungal metabolite with putative GRP78 inhibitory activity, was found 
to exhibit potent cytotoxic effects in breast cancer cell lines by inhibiting the mitochondrial 
energy production.
30 
This finding has fueled speculation that other supposed GRP78 inhibitors 
(e.g. arctigenin, deoxyverrucosidin, efrapeptin, piericidin,  pyrvinium, rottlerin, valinomycin) 
might also act in a GRP78-independent fashion.
30
  
 
Figure 4.5. Small molecule inhibitors of GRP78 activity.
28-30 
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Leading into biopolymer modulators of GRP78 activity, the serine protease subtilase 
cytotoxin was used to selectively cleave GRP78, thereby sensitizing apoptosis-resistant cancer 
cells to Photofrin-mediated photodynamic therapy (PDT).
31
 The discovery of a peptide ligand 
derived from the cochaperone Bag-1 has been shown to bind to and inhibit the refolding activity 
of GRP78 causing apoptosis in in vivo xenograft tumor models.
32 
Moreover, peptide ligands and 
circulating GRP78 antibodies have been identified to selectively bind cell surface GRP78 on 
tumor cells, forming the basis for GRP78 tumor-targeting approaches,
33
 as highlighted in 
Chapter 5.  
Knockdown of GRP78 has also been shown to sensitize cancer cells to chemotherapy or 
radiation treatments resulting in cancer cell death. For example, siRNA-mediated silencing of 
GRP78 expression enhanced the cytotoxic effects of fenretinide or bortezomid in CHL-1 and 
WM266-4 melanoma cells by two- to three-fold relative to the untransfected controls.
27
 siRNA 
transfection in primary cultures of human brain endothelial cells, derived from the blood vessels 
of malignant glioma tissues (TuBEC) reversed chemoresistance to a wide range of anti-cancer 
drugs including CPT-11, etoposide and temozolomide.
19b 
Similarly, GRP78 knockdown 
enhanced apoptosis in colon cancer DLD-1 cells following treatment with epirubicin. In this 
case, GRP78 silencing sensitized the cells to the cytotoxic drug treatment by decreasing 
intracellular levels of ROS and survival signaling of the Akt pathway.
34
 In a similar combination 
approach against human urothelial carcinoma cells, GRP78 knockdown potentiated the cytotoxic 
effects of celecoxib, a selective cyclooxygenase-2 inhibitor (COX-2).
35 
It is also worthwhile to 
note that while siRNA-mediated knockdown of GRP78 was found to reverse chemoresistance 
and enhance the cytotoxic effects of the anti-cancer drugs, silencing of GRP78 is in itself 
insufficient to stimulate apoptosis. These results confirms the synergy associated with GRP78 
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activity and cell survival, but also underscores the importance of targeting GRP78 in  
combination approaches that abolishes resistance in highly resilient and recurring tumors.        
 
4.3 CHAPTER OBJECTIVES 
 A novel GRP78 gene-targeting approach is described in this chapter with the use of 
linear, V-shape, Y-branch and   hyperbranch siRNAs (Figure 2.9).
42
 In this study conducted 
by Brittany Blackman
40
 and Christopher Parronchi in collaboration with Dr. Allan Blake 
(Department of Biological Sciences, Seton Hall University), siRNAs (Table 2.1, sequence no. 
1-7) were treated with Lipofectamine™ 2000 (Invitrogen, CA), and transfected in HepG2 liver 
hepatoblastoma cells to explore their biological activity (Figure 4.6). In order to confirm their 
suitability for the RNAi application, cell lysates are used to determine the total GRP78 content 
with and without siRNA treatment. In this case, western blotting with an anti-GRP78 antibody 
and a suitable secondary antibody for detection will be used to determine GRP78 expression 
levels in HepG2 cells. Moreover, laser scanning confocal microscopy will be used to monitor 
cell surface GRP78 expression levels with and without siRNA treatment. In order to investigate 
the anti-cancer activity of the siRNAs, a Trypan blue cell viability assay will be conducted. In 
this manner, the novel siRNAs synthesized (Chapter 2) and characterized (Chapter 3) will be 
evaluated for anti-cancer application.   
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Figure 4.6. GRP78 gene-targeting method with  hyperbranch siRNA:Lipofectamine 
complex
42 
 
4.4 RESULTS AND DISCUSSION 
4.4.1 HepG2 CELL CULTURE 
Hepatoblastoma (HB) is an embryonal form of liver cancer often found in the early stages 
of childhood.
35 
HepG2 hepatoblastomas are a relevant tumor cell line model for the pre-clinical 
study of pediatric liver diseases.
36
 The HepG2 cell line (ATCC, CA) is credited to Dr. Barbara 
Knowles and colleagues (Wistar Institute, PA) who extracted them from the liver tissue of a 15 
year old white male who had developed a well differentiated heptocellular hepatoblastoma back 
in 1979.
36,37 
Moreover, cell surface GRP78 expression has been correlated with tumor invasion in 
HepG2 cells making it a clinically relevant tumor model for validating our GRP78-targeting 
strategy.
38
 
 Based on literature precedence for the HepG2 cell culture
37,38
, HepG2
 
liver cancer cells 
(~5 x 10
4
 cells) were plated in 24-well culture plates and grown in DMEM with 10% fetal bovine 
serum for 48 h in a humidified incubator at 37 C with 5% CO2. Following a 24 h incubation 
period, the HepG2 cells were passaged and treated with a basal, serum free medium (OptiMEM) 
and incubated for an additional 24 h prior to analyses. Cell counting to discern viability was 
performed with a Countess automated cell counter using a Trypan blue exclusion assay. A rich 
population of HepG2 cells (50,000 cells/well), were maintained for siRNA transfections.  
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4.4.2 siRNA:LIPOFECTAMINE TRANSFECTIONS IN HepG2 CELLS 
 In order to facilitate cell penetration of the GRP78 targeting siRNAs, a suitable 
transfection reagent functions to bind siRNA and mask the negatively charged phosphodiester 
bonds for efficient translocation across the negatively charged amphiphilic plasma membrane. 
For example, Lipofectamine™ 2000, a cationic amphiphile forms an ionic complex with siRNA 
and ushers its delivery across the lipid bilayer for RNAi application. This reagent is the 
benchmark transfection agent for delivery of oligonucleotides inside cells.
39 
Prior to siRNA transfection, the toxicity of Lipofectamine™ 2000 was evaluated within 
HepG2 cells to determine a range in which this reagent can be used without triggering cell 
cytotoxicities.
40
 In this toxicity experiment, Lipofectamine™ 2000 (1 µg/well to 10 µg/well) was 
administered to the HepG2 cells in a 96-well plate (9 wells/treatment) and incubated for 48 h at 
37 C with 5% CO2. Following incubation, a Calcein AM cell viability assay
41
 was performed to 
determine cell viability with and without Lipofectamine treatment (Figure 4.7). In this assay, 
only cells treated with higher quantities of Lipofectamine (10 µg) exhibited a significant drop in 
cell viability (>50%). Thus, an effective range of Lipofectamine™ 2000 (1-7 µg) can be used for 
optimizing the siRNA transfection protocol.  
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Figure 4.7. Lipofectamine™ 2000 toxicity on HepG2 cells. HepG2 cells were plated 50,000 
cells/well in 96 well plate with 9 wells per treatment with Lipofectamine™ 2000 (0 – 10 
µg/well).  The number of viable cells/well after Calcein AM treatment is shown (n=1).
40,41 
 
 
 
 In order to test the optimal stoichiometric ratios for the Lipofectamine:siRNA complex to 
be used in the transfection experiments, increasing amounts of a linear control GRP78-targeting 
siRNA (20 - 80 pmol, Table 2.1, sequence no. 1) were tested with a nominal quantity of 
Lipofectamine (1 µg).
40
 Following transfection, Western blot
44
 and Trypan blue exclusion
45
 
assays were used to determine the extent of total GRP78 knockdown and HepG2 cell death, 
respectively.  The Western blot studies (Figure 4.8) revealed a dose-response relationship 
between the siRNA treatment (20 - 80 pmol) and GRP78 silencing (50-60%), illustrating the 
effectiveness of the siRNA:Lipofectamine complex in the RNAi application. In spite of these 
encouraging results, minimal HepG2 cell death (< 5%) was observed even at the highest siRNA 
doses (80 pmol) and extended incubation times (4 days). These results are not surprising, 
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considering GRP78 knockdown has been shown to be in itself insufficient for stimulating cell 
death,
42,43
 but however sensitizes cells to chemotherapeutic agents which can trigger 
apoptosis.
19b,27,34,35,38
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Figure 4.8. Western blot for the siRNA:Lipofectamine transfections.  A. Representative western 
blot (n=5) with varying concentrations of GRP78-targeting siRNA (20 - 80 pmol, Table 2.1, 
sequence no. 1); B.  GRP78 protein expression levels quantified using NIH Image J (n=5); 
statistical significance was determined by ANOVA (p< 0.05).
40,42 
 
 From this preliminary study (Figure 4.8), optimized methods for the 
Lipofectamine:siRNA transfection experiments were developed in HepG2 cells in order to 
deduce the influence of the GRP78-targeting siRNA constructs (Table 2.1, sequence no. 1-7) on 
RNAi activity.
40,42
 Briefly, siRNA samples (40 pmol) were transfected with Lipofectamine™ 
2000 (1 µg) in HepG2 cells (50,000 cells/well), and incubated in OPTIMEM at 37C with 5% 
CO2. Following transfection (48 h), cell lysates were prepared (RIPA lysis buffer, Invitrogen) 
and resolved by SDS PAGE for immunoblotting with an anti-GRP78 primary antibody and a 
secondary antibody conjugated to horseradish peroxidase (HRP). In this assay, total HepG2 
cells’ GRP78 expression levels were determined by the redox activity of the  3,3’,5,5’-
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tetramethylbenzidine (TMB) substrate.
44,46  
The gel (Figure 4.9 A) was analyzed by 
autoradiography and demonstrated effective silencing (40-60%) of GRP78 expression by linear 
(~40-60%, Table 2.1 sequence no. 1 and 2), V-shape (~50%, Table 2.1 sequence no. 4), Y-
branch (~55%, Table 2.1 sequence no. 5) and hyperbranch (~50-60%, sequence no. 6  and 7) 
siRNAs (Figure 4.9 B). These results confirms the GRP78-targeting and silencing effects of the 
linear siRNA controls (Table 2.1 sequence no. 1 and 2), but also underscores the unprecedented 
RNAi activity of the V-shape, Y-branch and  hyperbranch siRNAs.   
      Cell viability data was also collected following a Trypan blue cell staining assay
45
, to 
establish the extent of HepG2 cell death following GRP78 knockdown. In this assay, GRP78-
targeting siRNAs (Table 2.1 sequence no. 1-7) stimulated 10-20% HepG2 cell death. The 
observed cell death percentages for linear siRNA controls were consistent with those observed in 
the literature
43
, with approximately 5% (1), compared to about 15% with V-shape siRNA (4), 
about 10% with Y-branch siRNA (5) and ~15% with  hyperbranch siRNAs (7) (Figure 4.9 C). 
Interestingly, hyperbranch siRNA (Table 2.1 sequence no. 7), targeting double sites of GRP78 
mRNA exhibited more potent GRP78 knockdown (60% vs. 40%) and cell death (15% vs. 5%) 
relative to the linear controls (Table 2.1 sequence no. 1 and 2), highlighting its synergistic 
effects in the RNAi application. 
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Figure 4.9. Linear, branch and hyperbranch siRNAs transfection results in HepG2 cells. A: 
Western blot of HepG2 cells lysates showing GRP78 expression following transfection with 
linear (2) and (1+2) siRNA controls and with V-shape (4), branch (5) and hyperbranch siRNAs 
(6,7), B: GRP78 expression levels were detected by autoradiography and quantified using NIH 
ImageJ, C: Cell viability data determined by Trypan blue exclusion. The data shown are the 
mean  SEM for 3 or more experiments, each performed in duplicate and analyzed with 
GraphPad Prism 4.0 and statistical significance was determined by ANOVA (p< 0.05).
40,42
  
 
 
4.4.3 CELL SURFACE GRP78 EXPRESSION IN HepG2 CELLS 
 Confocal laser scanning microscopy was used to confirm the presence of cell surface 
GRP78 on HepG2 cells with an anti-GRP78 primary and a secondary antibody conjugated to 
fluorescein isothiocyanante (FITC).
40,42
 HepG2 cell images (Figure 4.10) were captured with a 
A 
B 
   -       2     1+2      4         5      6         7 MW 
(kDa) 
110 
  80 
  60 
GRP78 
β-actin 
C 
siRNA Constructs Western Blot 40 pmol
- 1 2 1+2 4 5 6 7
0.00
0.25
0.50
0.75
1.00
**
*
*p<0.05
*
*
*
*
siRNA Construct
M
e
a
n
 I
n
te
g
ra
te
d
 D
e
n
s
it
y
(G
R
P
7
8
)
Cell Viability
- 1 2 1+2 4 5 6 7
0
20
40
60
80
100
*
*p<0.05
*
siRNA Construct
P
e
rc
e
n
ta
g
e
 V
ia
b
le
 C
e
lls
 (
%
)
114 
 
40X oil objective lens, from which FITC labeled GRP78 stained green and DAPI-stained cell 
DNA shone blue (Figure 4.10, A). Cell surface GRP78 knockdown was subsequently assessed 
by transfecting the HepG2 cells with Lipofectamine:hyperbranch siRNA (40 pmol, Table 2.1 
sequence no. 7) followed by incubation at 37 
o
C for 48 hours. Following transfection, cells were 
plated on glass slides and treated with the same anti-GRP78 primary and FITC-labeled 
secondary antibodies to examine GRP78 expression levels (Figure 4.10, B). In this assay, 
hyperbranch siRNA 7 potently silenced GRP78 expression (~70% knockdown) as shown by the 
minimal ‘yellow’ FITC-signaling relative to the control untransfected cells (Figures 4.10, A - 
C). Moreover, these results also suggest that HepG2 cell GRP78 may be further exploited for the 
tumor-targeted delivery of siRNAs (Chapter 5).  
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Figure 4.10. Monitoring cell surface GRP78 expression with confocal laser microscopy of A. 
paraformaldehyde fixed HepG2 cells with an anti-GRP78 antibody (FITC; green) and DAPI 
(blue) nuclear stain. Cells were viewed using a 40X oil objective lens, and the cells are 
representative of separate viewing fields from two independent experiments.; B. HepG2 cells 
transfected and incubated (48 h) with hyperbranch siRNA (Table 2.1 sequence no. 7), fixed 
with 2 % paraformaldehyde and stained with DAPI (blue), and FITC conjugated to GRP78 
protein expression (green).; C. Percentage of the HepG2 cells with FITC-GRP78 signal for both 
the control and transfected sample.  Statistical significance determined with student’s t-test and p 
value < 0.05.
40,42     
 
 
 
4.5 CONCLUSIONS 
In this chapter the putative RNAi activity of the GRP78-targeting siRNAs (Table 2.1, 
sequence no. 1-7) has been validated in HepG2 hepatoblastomas.  The novel V-shape, Y-branch, 
and  hyperbranch siRNA motifs (Table 2.1, sequence no. 4-7) were found to solicit potent 
GRP78 silencing (50% – 60%). Significantly, hyperbranch siRNA, 7, targeting double sites of 
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GRP78 mRNA expression was found to trigger more potent GRP78 knockdown (60% vs. 40%) 
and HepG2 cell death (15% vs. 5%) highlighting its synergistic effects relative to the linear 
control siRNAs, 1 and 2. This finding is important for the development of new siRNA constructs 
that may target multiple genes in a combination approach for improving RNAi efficacy and also 
for screening new oncogene targets. Moreover, confocal laser scanning microscopy also 
confirmed potent cell surface GRP78 knockdown (~70%) with hyperbranch siRNA, 7. 
Interestingly, FITC-labeling of GRP78 on the cell surface of HepG2 cells suggests the possibility 
of developing a tumor-targeting approach for the selective delivery of siRNAs in cancer cells. 
The latter is a focal point of the final thesis chapter (Chapter 5), which highlights the preliminary 
studies towards the development of a cancer-targeting gene therapy approach.    
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4.7 EXPERIMENTAL SECTION 
4.7.1 HepG2 CELL CULTURE 
 The human hepatoblastoma, HepG2 cells (American Type Culture Collection, 
Manhasset, VA) were cultured in T25 cm
2 
and T75 cm
2
 flasks (Grenior Bio-one Cell star, FL) in 
Dulbecco’s Modified Eagle Medium (DMEM) with GlutaMAX and heat-inactivated 10% Fetal 
Bovine Serum (Gibco, CA), containing 1% penicillin/streptomycin (Gibco, CA), in an incubator 
set at 37 
o
C with a humidified atmosphere of 5% CO2. Cells were routinely passaged at 75% 
confluence using Dulbecco’s PBS (Gibco, CA) and 0.05% Trypsin-EDTA (1X), Phenol Red 
(Gibco, CA) and then split into a 1:10 dish ratio.  Cells used in the transfection experiments were 
cultured in 6- 96-well culture plates and allowed to recover for 24 hours before treatment.        
 
4.7.2 siRNA PREPARATION  
A solution of each single strand siRNA (50 µM) was prepared by taking an aliquot from 
the crude stock and adding millipore water to give the required concentration. From these stock 
solutions (50 µM), siRNAs (30 µL) were combined in a microcentrifuge tube and treated with 
annealing buffer (15 µL of 5X Annealing Buffer: 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5.0 
mM EDTA) to give a final volume, 75 µL (20 µM). The solution was then heated at 95 
o
C (1 
min) to denature higher-order structure, centrifuged and allowed to slow cool at room 
temperature (1 h) before being placed in the fridge overnight for hybrid formation. The resulting 
duplexes were frozen at – 20 oC until use. 
 
4.7.3 siRNA TRANSFECTION IN HepG2 CELLS 
HepG2 cells were transfected with the appropriate siRNA, 1-7, (40 pmol) and 
Lipofectamine™ 2000 (1 µL) according to the manufacturer’s instructions.  Briefly, 5 x 104 cells 
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were plated in 24-well culture plates containing DMEM (10% fetal bovine serum) and 
maintained for 48 h in a humidified incubator at 37 C with 5% CO2.  Twenty four hours prior to 
transfection the cells were switched to a basal, serum free medium (OptiMEM).  Transfections 
were performed with Lipofectamine™ 2000 (1 µL) and the appropriate siRNA, 1-7, (40 pmol 
siRNA in 50 µL of OPTIMEM).  The siRNA-Lipofectamine complexes were incubated at room 
temperature for 20 min, added to the cell monolayers and the plates were incubated at 37 C with 
5% CO2.  After 24 h, the serum free basal medium was removed and replaced with growth 
medium. Transfected cells were harvested 48 h after transfection for analysis. 
 
4.7.4 SDS-PAGE and WESTERN BLOTTING 
 Parallel cultures of HepG2 cells were prepared with serum-free basal medium (Opti-
MEM) for 24 h and then incubated in the presence or absence of varying concentrations of 
siRNAs (1-7) for 48 hours at 37 ˚C. Cell lysates were prepared with RIPA lysis buffer, heated to 
70 ˚C for 10 min., resolved on NuPAGE 10% Bis-Tris gels and electroblotted onto 
polyvinyldifluoride (PVDF) membranes. Membranes were treated for 90 min in a blocking 
buffer containing 5% (w/v) of non-fat dehydrated milk to minimize non-specific binding. Total 
HepG2 cells’ GRP78 expression was immunodetected with a 1:200 final dilution of anti-GRP78 
N-20 antibodies.  The membrane associated immunoreactivity was then detected using a 1:5000 
dilution of a horseradish peroxidase-conjugated anti-goat secondary antibody and detected using 
ECL Plus chemiluminescence.  The resulting autoradiograph was scanned, quantified with NIH 
ImageJ and expressed as integrated pixel density.   
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4.7.5 CONFOCAL MICROSCOPY 
  HepG2 cells were plated at a cell density of 15,000 cells/well on 4 well chamber glass 
slides.  Cells were transfected and incubated for an additional 48 hours prior to confocal 
microscopy.  Cells were then rinsed with Serum free DMEM, and fixed on the glass slides with 
2% paraformaldehyde in PBS (Gibco, CA) for 10 minutes. The samples were then blocked in 
10% rabbit serum for 30 minutes, incubated in goat-anti human GRP78 N-20 antibody (Santa 
Cruz Biotechnology, CA) 1:75 dilution in 2.5% rabbit serum in PBS for 2 hours at room 
temperature.  After PBS washing the slides were incubated in goat anti-rabbit conjugated with 
Fluorescin isothiocyanate (FITC) antibody in 2.5% rabbit serum in PBS for 50 minutes and 
Vectorshield (Vector Laboratories, CA) covered to protect from photobleaching.  Slides were 
counterstained with 4’,6-diamino-2-phenylinode (DAPI) in 0.50 g/mL in PBS for 3 minutes 
and then a mounting medium with fluorescence was added with coverslips.  Slides were viewed 
on a Confocal Laser Scanning Microscope (Olympus, MA) with a 40X oil objective lens in 
conjunction with the Olympusview program.    
 
4.7.6 CELL VIABILITY  
Cell viability was determined in 24-well plates with HepG2 cells cultured in serum-free 
basal medium for 24 h and then incubated in the presence or absence of varying concentrations 
of Lipofectamine 2000 (1-10 g) and siRNAs (20-80 pmol, 1-7) for 48 h at 37 o C.  The samples 
were removed with Enzyme Free Dissociation Buffer (Invitrogen, CA) for 3 minutes at 37 C. 
Samples were pelleted and re-suspended in Dulbucco’s PBS (1 mL) and Trypan blue 0.4% stain 
(100 µL) was added. Samples were quantified using a Countess automated cell counter 
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(Invitrogen, CA). The resulting data was analyzed with GraphPad Prism 4.0 and statistical 
significance was determined by ANOVA (p< 0.05). 
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CHAPTER 5. PRELMINARY STUDIES TOWARDS THE DEVELOPMENT 
OF A CANCER-TARGETING GENE THERAPY APPROACH 
 
5.1 ABSTRACT 
Linear, branch and hyperbranch GRP78 siRNAs proved to be valuable substrates for silencing 
GRP78 expression (50-70%) and triggering cell death (5-15%) in a HepG2 hepatoblastoma 
cancer cell line (Chapter 4). In this chapter, preliminary results which showcase the combination 
of GRP78-targeting siRNAs and peptides (i.e. cancer-targeting peptides, CTPs) are described 
towards the development of a cancer-targeting gene therapy approach. In this method, linear, 
branch and hyperbranch GRP78-silencing siRNAs are complexed with poly(arginine) derived 
GRP78-targeting peptides that may usher the selective delivery of siRNAs into GRP78 harboring 
tumor cells for RNAi and cell death activity. The complexes formed between the CTPs:siRNAs 
were effectively characterized by native PAGE, CD spectroscopy, thermal denaturation, DLS 
and TEM experiments which demonstrated the formation of stable, higher-ordered complexes. 
Moreover, the direct transfection of a linear GRP78 silencing siRNA (Table 2.1, sequence no. 
1) with a CTP derived from the Pep42-R9 sequence demonstrated significant GRP78 silencing 
(50-60%) and modest cell death (5-15%) in HepG2 cells which mirrored the results obtained 
from the benchmark Lipofectamine:siRNA transfection studies (Chapter 4). These results 
suggests that the Pep42-R9 sequence and related CTPs may function as useful GRP78-targeting 
transfection agents in a wide range of cancer cell types that display cell surface overexpression 
of GRP78. This discovery is important for the development of an effective cancer-targeting gene 
therapy approach, which aims to kill cancer cells selectively, while leaving the healthy ones 
unscathed.   
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5.2 INTRODUCTION 
5.2.1 SELECTION OF PEP42 AS A GRP78-TARGETING PEPTIDE 
 The selection of Pep42, a cyclic peptide composed of CTVALPGGYVRVC was 
discovered from a library of short cyclic peptide sequences expressed on the surface of M13 
filamentous phage.
1
 In a process referred to as whole cell phage display biopanning
2
, the 
peptides coated on the phage surface were screened against highly metastatic melanoma cells 
(Me6652/4) and a low metastatic clone as control (Me6652/56) for cell binding affinity and 
specificity. Following multiple rounds of evolution and selection, phages which strongly 
adsorbed on the surface of highly metastatic melanoma cells but not on the low metastatic clone 
were isolated and analyzed to determine the identity of the peptide and receptor involved in the 
binding interaction.   The corresponding peptide sequence, Pep42, was found to exhibit high 
affinity and selective binding to GRP78, even relative to the homologous heat shock protein, 
Hsp70, chaperone and the ubiquitous bovine serum albumin, BSA, a surrogate for serum proteins 
(Figure 5.1).
3
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Figure 5.1. Binding assay of the Pep42 phage with recombinant proteins. Pep42 phage 
demonstrates high binding affinity and specificity for GRP78. Figure adapted from reference 3. 
The cell surface Pep42:GRP78 binding selectivity was also explored on human cancer 
cell lines, including the highly metastatic melanoma cells (Me6652/4), lung adenocarcinoma 
cells (A549), osteocarcinoma cells (A549) and HepG2 hepatoblastoma cells relative to two 
normal human fibroblast cell lines (HDFa and CCD-11Lu).
3 
Significantly, FITC-labeled Pep42 
was found to bind to the human cancer cells but not the normal cell line controls according to 
flow cytometry. The same observation was also noticed with the FITC-labeled monoclonal 
antibody specific for GRP78, suggesting that the Pep42:GRP78 interaction may be responsible 
for tumor binding selectivity. In order to validate this hypothesis, a polyclonal antibody was used 
to block GRP78 on the surface of HepG2 cells, followed by treatment with FITC-labeled Pep42. 
This resulted in a decrease in the fluorescence signaling from the FITC-Pep42 probe. A similar 
decrease in fluorescence signaling from the FITC-Pep42 conjugate was observed following a 
GRP78-silencing siRNA treatment, illustrating the importance of the GRP78 cell surface 
receptor for Pep42 binding.  
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Confocal laser scanning fluorescence microscopy was used to support the Pep42:GRP78 
binding interaction on the surface of tumors and examine whether the peptide exhibited cell 
permeability.
1,3 
In this study, a derivative of Pep42, Mut42, which replaced the valine at position 
10 with a lysine to facilitate the incorporation of the FITC label was used to ascertain cell 
translocation activity. It is imperative to note that this site specific substitution in Pep42 was not 
found to alter its GRP78 binding activity. Thus, treatment of FITC-labeled Mut42 with 
metastatic melanoma cells (Me6652/4) and the low metastatic control (Me6652/56) resulted in 
greater uptake within the tumorigenic melanoma cells (Figure 5.2, i).
1
  Similarly, Mut42-
quantum dots (Mut42-QD) were prepared and applied for detecting cellular localization with 
greater sensitivity relative to their fluorescent counterpart. In this case, the Mut42-QD probes 
were found to translocate and localize within the cytosol of highly metastatic melanoma cells 
without entering their nucleus. Further investigation revealed that the Mut42-QD co-localized in 
the endoplasmic reticulum with the co-administration of Glibenclamide, a biomarker that stains 
the ER (Figure 5.2, ii). 
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Figure 5.2. Cell uptake (i.) and localization (ii.) of Mut42. i. Comparison of the cell uptake of 
Mut42-FITC in (a) highly metastatic melanoma cells (Me6652/4) and (b) low metastatic 
melanoma cells (Me6652/56). Mut42-FITC green signal apparent in (a) but not in (b). ii. Cellular 
co-localization of Mut42-QD in the ER of highly metastatic melanoma cells (Me6652/4) with 
Glibenclamide. Figure adapted from reference 1. 
 
 Confocal microscopy was also employed to elucidate the mechanism of Pep42 cell 
translocation.
3 
A Pep42-QD was prepared and applied to discern the mechanism of 
internalization in A549 osteocarcinoma cells. In this assay, Pep42 was found to partially co-
localize with known markers of endocytosis such as transferrin and cholera toxin subunit B. 
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Transferrin glycoproteins have been found to internalize within cells by an endocytosis pathway 
which involves the formation of clathrin-coated vesicles at the cell surface.
4
 Whereas, the 
cholera toxin subunit B internalizes within cells by caveolae-mediated endocytosis.
5
 In order to 
delineate the endocytosis pathway of Pep42, several inhibitors of endocytosis were examined, 
including chlorpromazine, a known inhibitor of clathrin mediated endocytosis.
6
 In its presence, 
Pep42 and transferrin did not internalize within A549 osteocarcinoma cells; whereas 
chlorpromazine had no effect on cholera toxin subunit B.
3
 These results suggests that Pep42, in 
similar fashion to transferrin, internalizes within A549 osteocarcinoma cells by a clathrin-coated 
endocytosis pathway.   
 In light of Pep42’s GRP78 targeting and internalization within cancer cell types but not in 
healthy ones, Pep42 was tested as a targeting drug delivery agent for anti-cancer applications.
1,3,7
 
Towards this goal, Pep42 has been effectively conjugated with cytotoxic anti-cancer drugs such 
as Taxol and Doxorubicin, photosensitizers such as a functionalized hematoporphyrin for 
applications in photodynamic therapy and the pro-apoptotic D-(KLAKLAK)2 sequence 
triggering programmed cell death specifically in human cancer cells and in xenograft mouse 
models.
1,3,7
 Thus, the highly specific Pep42:GRP78 ligand-receptor interaction may form the 
basis for new and improved drug delivery methods in cancer treatment. 
 
 5.2.2 POLY(ARGININE) PEPTIDES AS siRNA CELL DELIVERY AGENTS 
 Poly(arginine) peptides encompass a special class of cell-penetrating peptides (CPPs) that 
have the ability to participate in ionic binding interactions with negatively charged biomolecules 
and cell-membrane translocation activity.
8
 Moreover, the number of arginine residues within the 
CPPs have been found to influence membrane permeability, with poly(arginine) sequences 
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containing in between 6-12 arginine residues eliciting optimal permeability and localization 
within the cytosol or nucleus of the cell.
8,9
 Their translocation mechanism is still widely debated, 
from which the nature of the arginine-rich sequence, its secondary structure and cell types have 
each been found to influence its membrane permeability and cellular localization.
8-10
 Moreover, 
 
poly(arginine) peptides have typically shown minimal cellular cytotoxicities
9
, facilitating their 
applications in the delivery of biomolecules across the plasma membrane. Specifically, 
poly(arginine) peptides have been employed in siRNA transfections due to their favorable ionic 
binding interactions with the negatively charged phosphodiester backbone of the oligonucleotide 
sequences. For example, human epidermal growth factor receptor 2 (HER-2) silencing siRNA 
has been effectively transfected within Cos-7 cells and in subcutaneous tumor transplants in mice 
with an arginine peptide (R15) leading to potent down-regulation of HER-2 mRNA and marked 
decrease in tumor size over a 17 day treatment regimen (Figure 5.3).
11
 Although arginine-rich 
peptides are highly efficient in mediating siRNA cellular uptake for RNAi activity in vitro and in 
vivo, their translation from pre-clinical to clinical use has been hindered by poor specificity and 
widespread toxicity, as these peptides and their cargo are dispersed in almost all tissues.
12 
In 
order to address this limitation, cancer-targeting peptides have been associated with 
poly(arginine) sequences to effect targeted cell delivery of siRNA in vitro and in vivo.
13
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Figure 5.3. Tumor growth in xenograft mouse with (A) no treatment, (B) siRNA, (C) 
R15:mismatch HER-2 siRNA and (D) R15:HER-2 siRNA following a 17 day treatment regimen. 
Transfection of R15:HER-2 siRNA shrunk the tumor size by more than 7 times relative to the 
un-treated control. Figure adapted from reference 11.  
 
5.3 CHAPTER OBJECTIVES 
 This chapter sets the stage for the development and application of a cancer-targeting gene 
therapy approach (Figure 5.4). Towards this ultimate goal, preliminary results are highlighted in 
this chapter that demonstrates the effective formation of GRP78-targeting CTP:siRNA 
complexes and their application in RNAi. This endeavor was partially accomplished in 
collaboration with Stesha Joseph (Dr. Sabatino’s group) who synthesized and characterized the 
CTPs used in this study and assisted in their complex formation/ characterization studies. TEM 
and dynamic light scattering (DLS) measurements were obtained at Queens College with the 
135 
 
assistance of Reeta Yadav, a graduate student in Dr. Samuni’s research group. Additionally, 
Brittany Blackman, Christopher Parronchi, Megan Kelly (Dr. Blake’s group) and Mariana 
Phillips (Dr. Sabatino’s group) have conducted the preliminary biological studies reported in this 
chapter and continue to investigate the bio-activity of the CTP:siRNA constructs. More 
specifically, complex formation between the CTP:siRNA ionic particles was validated by native 
PAGE, thermal denaturation, CD spectroscopy, DLS and TEM experiments. These methods 
served to elucidate the optimal stoichiometric ratios of the CTPs and siRNAs necessary for 
complex formation, thermal stabilities, particle size distributions and the structures of the higher-
ordered assemblies. Prior to RNAi application, the serum stability of the CTP:siRNA complexes 
relative to their individual components was examined in 10% fetal bovine serum (FBS) to 
determine their resistance towards degradation in biological media. With stable CTP:siRNA 
complexes in hand, their potential in RNAi application is discussed en route towards the 
development of an effective cancer-targeting approach.   
Figure 5.4. Proposed cancer-targeting gene therapy strategy  
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5.4 RESULTS AND DISCUSSION 
5.4.1 PREPARATION AND CHARACTERIZATION OF CTP:siRNA COMPLEXES 
 
With pure samples of linear, V-shape, Y-branch and  hyperbranch siRNAs (Table 2.1, 
sequence no. 1-7) and CTPs containing the GRP78-targeting Pep42 with varying poly(arginine) 
sequences
14
, the optimal stoichiometric ratio for CTP:siRNA complex formation was established 
by native PAGE. Stoichiometric ratios of 1-50:1, CTP:siRNA were combined in an annealing 
30% sucrose (Tris-Acetate-EDTA) TAE buffer pH 8.3, incubated for 30 min at 37 
o
C and loaded 
on a native PAGE absent of urea. Samples were resolved on the native gel and detected by 
staining with a Stains All™ dye (Aldrich) which forms a dark blue colored complex with the 
oligonucleotides.
15
 From this gel shift assay, increasing mole ratios of a CTP (1.0-50 μmol, 1-50) 
bearing a nona-arginine sequence (R9) relative to a single-stranded siRNA control (1.0 μmol, 
Table 2.1, sequence 3) produced shifts in the electrophoretic mobilities of the forming 
CTP:siRNA complexes (Figure 5.5). Specifically, at a stoichiometric ratio of 50:1 CTP:siRNA 
formed a slower moving band indicative of a higher-ordered complex relative to the single strand 
siRNA control. 
 
Figure 5.5. Native PAGE gel shift assay. Linear single strand siRNA (1.0 μmol, Table 2.1, 
sequence 3) and increasing (1-50:1) stoichiometric ratios of CTP (1.0 – 50 μmol, Pep42-R9). 
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Similarly, this CTP sequence was found to effectively produce higher-ordered complexes at a 
mole ratio of 50:1 with double-stranded, Y-shape and  hyperbranch siRNAs (Table 2.1, 
sequence nos. 2, 5 and7) by native PAGE (Appendix C). 
 
CD spectroscopy was then used to assess the changes in CTP and siRNA structures in their 
free form and bound state (Figure 5.6). The cyclic Pep42-R9 sequence demonstrated a CD 
spectrum that contained an ordered turn conformation with minimal random coil observed. Some 
types of peptide turn geometries have been characterized by a minimum band at around 210 nm 
and maximum molar ellipticities centered around 220 and 190 nm (Figure 5.6, i).
16 
Conversely, 
disordered peptide structures or random coils have strong negative bands centered around 190 
nm.
17
 The linear siRNA control (Table 2.1, sequence 1) demonstrated a typical CD profile for 
the canonical double-stranded A-form RNA helix (Chapter 3), displaying a minimum peak at 
around 240 nm and a broad maximum in between 255-290 nm (Figure 5.6, ii).
18
 In combination, 
the CTP:siRNA complexes exhibited profound changes on their respective secondary structures 
(Figure, 5.6, iii) and produced higher–ordered structures that were atypical of the putative CTP 
turn conformation or siRNA A-type helix. Similar trends were observed for the remaining 
CTP:siRNA complexes (Appendix D). 
 
Figure 5.6. CD spectra of i. CTP: Pep42-R9 (0.1 mg/mL), ii. siRNA (0.26 μmol, Table 2.1, 
sequence 1) and iii. CTP:siRNA complexes (13 μM, 1-50:1 mol/mol) in PBS (137 mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4 adjusted to pH 7.4) at 25 
o
C. 
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In order to determine the sizes, shapes and structures of the CTP:siRNA complexes, DLS 
and transmission electron microscopy (TEM) experiments were conducted. DLS was initially 
employed to investigate the size distributions of the particles formed between the CTP:siRNA 
relative to their individual components (Table 5.1). DLS measurements of the effective 
diameters (nm) observed from the nanoparticles indicated a uniform size distribution for the 
CTP, Pep42-R9 (~ 40 nm) and aggregates for the linear siRNA (Table 2.1, sequence no. 2, 600-
1000 nm, and a monomer size of 20 nm). Comparatively, the CTP:siRNA complex (13 μM, 50:1 
CTP:siRNA) displayed a bimodal size distribution according to the DLS measurements, with one 
distribution occurring at around 210 nm and a much larger one at about 1400 nm. The latter 
results in more than a 50-fold increase in CTP:siRNA particle size relative to the unbound 
components, validating the formation of higher-ordered complexes. Similar trends were observed 
from the DLS measurements obtained for the CTP:siRNA complexes formed in between the 
Pep42-R9 sequence and the Y-shape (Table 2.1, sequence no. 5),  hyperbranch (Table 2.1, 
sequence no. 7) siRNAs (Appendix E). 
 
Table 5.1 DLS measurements of the effective diameters (nm) observed.
a
 
 
Samples  Effective Diameters (nm) 
CTP, Pep42-R9 40 ± 4 
Linear siRNA, 2 (monomers) ~ 20  
CTP:siRNA 210 ± 14 
1400 ± 80 
a
Samples (0.05-0.15 μM) were prepared in pre-filtered (0.2 μm filter) pH 7.0 phosphate buffer 
(140 mM KCl, 1 mM MgCl2, 5 mM NaHPO4) and sonicated for 30 minutes before taking 
measurements. The reported diameter is the average of 5 runs for each sample reported with 
standard deviations about the mean.  
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The TEM images provided an illustration of the shapes and structures formed from the 
CTP:siRNA complexes (Figure 5.7). In the case of the complex formed between a CTP, Pep42-
R9 and a linear siRNA sequence (Table 2.1, sequence no. 2) the particles appeared as spherical 
shaped aggregates with approximate diameters of 1000 nm, that were in agreement with those 
observed from the DLS measurements. Moreover, similar results were also obtained for the 
remaining CTP:siRNA complexes (Appendix F), highlighting the efficiency of the Pep42-R9 
sequence in condensing siRNAs of varying lengths, sequences and morphologies. These results 
were also in agreement with the TEM images reported for a myristoylated cell-penetrating 
peptide with a transferrin receptor-targeting sequence bound to siRNA for RNAi application.
19
 
Thus, the ability for the CTP sequence to effectively condense siRNA into stable nanoparticle 
formulations is an important requirement for their biological applications.  
 
     
Figure 5.7. TEM image of the complex formed between Pep42-R9 and linear siRNA (Table 2.1, 
sequence no. 2). Samples (0.13 μM) were mixed with 1% uranyl acetate in ethanol (1:1 v/v), 
sonicated for 10 minutes, and added to a carbon film coated copper grid, 300 mesh (Electron 
Microscopy Sciences, PA) and dried overnight prior to viewing under the transmission electron 
microscope (JEOL, model JEM-1200 EX). Images were taken with a SIA–L3C CCD camera 
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(Scientific Instruments and Applications, Inc., GA) using the software Maxim DL5 (Diffraction 
Limited, Ottawa, Canada). 
 
Thermal denaturation experiments were next conducted to determine the thermal stability 
of the CTP:siRNA complex. In the absence of peptide, the double-stranded siRNA (Table 2.1, 
sequence no. 2) exhibited a helix-to-coil transition
18
 with increasing temperatures (5-90 
o
C) that 
produced a noticeable change in hyperchromicity (%H: 5-30%) and thermal denaturation 
temperature (Tm: 72 
o
C). This data is consistent with that reported for the linear, V-shape, Y-
branch and  hyperbranch siRNAs described in this study (Chapter 3). Titration of CTP (0.26 – 
13 μmol) to siRNA (0.26 μmol) produced striking changes in the thermal denaturation curves 
(Figure 5.8). These changes were associated with a sharp decrease in hyperchromicities (30% to 
≤10%) which abolished the single phase transition observed in the control (free-form) siRNA. 
Presumably, at optimal CTP:siRNA (15 μM, 50:1 mol/mol) concentrations the siRNA no longer 
exhibits the characteristic biophysical traits of a double-stranded RNA hybrid. Similar trends 
were observed in the thermal denaturation curves of the remaining CTP:siRNA complexes 
(Appendix G).   
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Figure 5.8. Thermal denaturation studies of the CTP:siRNA complex. Samples were prepared by 
mixing CTP:siRNA (15 μM, 1-50:1 mol/mol) in phosphate buffer (140 mM KCl, 1 mM MgCl2, 
5 mM NaHPO4) and placing on a heat block incubator set at 37 
o
C for 1 hour. Samples were 
cooled to room temperature and placed in the fridge overnight for use the next day. 
 
5.4.2 BIOLOGICAL STUDIES OF THE CTP:siRNA COMPLEXES 
The ability for the CTP:siRNA complexes to retain metabolic stability is an important 
requirement for their fruitful RNAi applications. This is because the native siRNA sequences are 
typically prone to nuclease digestion in biological media, limiting their therapeutic potential.
20
 
Samples were subjected to a 10% fetal bovine serum (FBS) in Dulbecco’s Modified Eagle 
Medium (DMEM) treatment in order to test the metabolic stability of the CTP:siRNA complex 
relative to the free-form siRNA. Aliquots were taken at measured time point intervals and run on 
a denaturing (urea) PAGE to resolve the samples. Stains-All™ (Aldrich) detection produced the 
desired siRNA bands with and without the CTP (Figure 5.9).  Excitingly, the CTP:siRNA 
complexes remained intact up to 8 hours,  (Figure 5.9, B) while in the naked siRNA produced 
short degradation products that were visible as lower migrating bands on the gel even after 5 
minute FBS treatment (Figure 5.9 A). The ability of peptides to confer nuclease resistance to 
-30 
-20 
-10 
0 
10 
20 
30 
0 20 40 60 80 100 
%
 H
yp
e
rc
h
ro
m
ic
it
y 
Temperature (oC) 
siRNA 
siRNA:CTP (1:1) 
siRNA:CTP (1:25) 
siRNA:CTP (1:50) 
142 
 
siRNA is not unexpected, peptide:siRNA complexes remained stable (> 8 hours) while the free-
form siRNA was completely degraded within 4 hours in 50% FBS.
19
   
 
 
 
Figure 5.9. 18% native (no urea) PAGE of (A) siRNA (20 μM) and (B) CTP:siRNA (20 μM) in 
10% FBS in DMEM. Samples were incubated (0.15 mL, 10% FBS/DMEM) at 37 
o
C and at 
measured time points, aliquots (10 μL) were treated with gel loading buffer (10 μL of 80 % 
formamide in TBE), heated at 95 
o
C and resolved on denaturing PAGE. The gels were stained 
with Stains-All™ (Aldrich) to view the siRNA decomposition patterns. 
 
With stable constructs in hand, the RNAi activity of the CTP:siRNA complex was next 
evaluated in HepG2 cells (Figure 5.10). A CTP:siRNA complex (50:1 mole ratio, 20 M) was 
prepared in a suitable binding buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM EDTA) 
for transfection within the HepG2 monolayers. The cells were incubated and cultured (48 h, 37 
o
C, 5% CO2) prior to analysis. Following incubation, cell lysates were prepared (RIPA lysis 
buffer, Invitrogen) and resolved by SDS PAGE, transferred to a PVDF membrane and 
immunoblotted with an anti-GRP78 primary antibody and a secondary antibody coupled to 
horseradish peroxidase (HRP). GRP78 expression levels were detected by autoradiography 
which produced reduced GRP78 (~50%) at quantities that were comparable to the benchmark 
Lipofectamine:siRNA transfections reported in Chapter 4. This experiment thus validates the 
utility of the CTP as an siRNA transfection agent for RNAi activity in HepG2 cells (Figure 5.10, 
143 
 
A, B). Finally, a Trypan blue cell staining assay was used to track the number of dead HepG2 
cells (~15%) following GRP78 silencing (Figure 5.10, C).  
 
Figure 5.10. RNAi activity of CTP:siRNA complex. (A) Western blot and (B) data analysis by 
autoradiography of GRP78 expression (n=1) following CTP:siRNA transfection (0, 40 and 80 
pmol siRNA, 50:1 mole ratio CTP:siRNA, in Tris buffer pH 8). (C) Cell viability data (0, 40 and 
80 pmol siRNA, 50:1 mole ratio CTP:siRNA, 20 µM in 50 µL of OPTIMEM) determined by 
Trypan blue exclusion (mean   S.E.M.; n=3, *P< 0.05). 
 
5.5 CONCLUSIONS 
 An entry point into a cancer-targeting gene therapy approach has been realized. In this 
chapter, a representative CTP:siRNA complex has been formulated and characterized by 
electrophoresis, spectroscopy and microscopy. Moreover, the CTP:siRNA complex was entirely 
stable (up to 8 hours) to a 10% FBS in DMEM treatment, highlighting the shielding effects of the 
CTP in protecting the siRNA from nuclease degradation in biological media. This feature is an 
imperative requirement for increasing the therapeutic index of the siRNA in the RNAi 
application.
20
 Towards this effect, the GRP78-targeting CTP:siRNA complex effectively down-
regulated GRP78 expression (~50%) in HepG2 hepatoblastoma cells while triggering noticeable 
apoptosis (~15%). Thus, the CTP:siRNA complexes formulate an effective transfection strategy. 
Future work is geared towards validating the remaining siRNAs (Chapter 2, Table 2.1) for RNAi 
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application, while exploring the influence of the poly(arginine) sequences on Pep42 targeted 
delivery of the siRNAs in GRP78 overexpressing tumors. The latter forms the basis of our 
cancer-targeting gene therapy approach, which has been partially realized by the notable 
contributions highlighted in this thesis.       
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5.7 EXPERIMENTAL SECTION 
5.7.1 CTP:siRNA COMPLEX FORMATION 
Pep42-R9 was added in increasing stoichiometric quantities (0.50 – 25 μmol) relative to the 
siRNA (0.50 μmol) in annealing buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM EDTA). 
The samples were incubated at 37 
o
C for 1 hour and left to cool down to room temperature and 
stored in the fridge (4 
o
C) overnight prior to use the next day. 
 
5.7.2 CTP:siRNA STABILITY IN 10% FBS/DMEM  
CTP:siRNA complexes and native siRNAs were incubated in 10% FBS/DMEM (150 μL) at 37 
o
C. Aliquots (10 μL) were removed at set time intervals (0-24 h), treated with gel loading buffer 
(10 μL of 80 % formamide in TBE loading buffer) and heated at 95 oC to quench the reactions. 
Samples were loaded and resolved on an 18% denaturing PAGE (7M urea) and visualized with 
Stains-All™ (Aldrich) to determine the siRNA integrity. 
 
5.7.3 GEL SHIFT ASSAY 
CTP:siRNA complexes (15 M, 1-50:1 mol/mol) were analyzed by native (no urea) PAGE. 
Samples were prepared by adding stoichiometric ratios (1-50:1) of CTP:siRNA in 30% sucrose 
in 1X TAE loading buffer (10 μL).  Samples were incubated at 37 oC for 1 hour, cooled to room 
temperature and stored at 4 °C overnight. A 18% native PAGE was prepared using 5 mL of 10X 
TBE buffer, 22.5 mL (acrylamide and N,N-methylene bisacrylamide) and 22.5 mL of autocalved 
water. The gel was run at 500 V for 2.5 h and stained with Stains-All™ (Aldrich) to visualize the 
CTP:siRNA bands. 
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5.7.4 DYNAMIC LIGHT SCATTERING (DLS)  
DLS measurements were performed on a 90 plus particle size analyzer (Brookhaven Instruments 
Corporation, NY) employing a 90° scattering angle and a 35 mW incident laser (658 nm). 
Samples were diluted in a pH 7 buffer consisting of 140 mM KCl, 1 mM MgCl2, 5 mM NaHPO4 
and sonicated for 30 minutes before taking measurements. The reported diameter is the average 
of 5 runs for each sample with the corresponding standard deviation.  
  
5.7.5 TRANSMISSION ELECTRON MICROSCOPY (TEM)  
The diluted samples from the DLS measurements were mixed in a 1:1 (v/v) ratio with 1% uranyl 
acetate in ethanol and sonicated for 10 minutes. An aliquot (5 L) was transferred to a carbon 
film coated copper grid, 300 mesh (Electron Microscopy Sciences, PA) and the excess solution 
was removed immediately using an absorbent paper. The grids were dried overnight and viewed 
under the transmission electron microscope (JEOL, model JEM-1200 EX). Images were taken 
with a SIA–L3C CCD camera (Scientific Instruments and Applications, Inc., GA) using the 
software Maxim DL5 (Diffraction Limited, Ottawa, Canada). 
 
5.7.6 HepG2 CELL CULTURE 
 The human hepatoblastoma, HepG2 cells (American Type Culture Collection, VA) were 
cultured in T25 cm
2 
and T75 cm
2
 flasks (Grenior Bio-one Cell star, FL) in Dulbecco’s Modified 
Eagle Medium (DMEM) with GlutaMAX and heat-inactivated 10% Fetal Bovine Serum (Gibco, 
CA), containing 1% penicillin/streptomycin (Gibco, CA), in an incubator set at 37 
o
C with a 
humidified atmosphere of 5% CO2. Cells were routinely passaged at 75% confluence using 
Dulbecco’s PBS (Gibco, CA) and 0.05% Trypsin-EDTA (1X), Phenol Red (Gibco, CA) and then 
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split into a 1:10 dish ratio.  Cells used in the transfection experiments were cultured in 6- 96-well 
culture plates and allowed to recover for 24 hours before treatment.        
 
5.7.7 CTP:siRNA TRANSFECTION IN HepG2 CELLS 
HepG2 cells were transfected with the appropriate siRNA, 1, (40-80 pmol) and CTP (4.0 
nmol) in binding buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM EDTA).  The cell 
monolayers were plated and incubated at 37 C with 5% CO2. After 24 h, the serum free basal 
medium was removed and replaced with growth medium. Transfected cells were harvested (48 
h) after transfection for analysis. 
 
5.7.8 SDS-PAGE AND WESTERN BLOTTING 
 Cell lysates were prepared with RIPA lysis buffer, heated to 70 ˚C for 10 min., resolved 
on NuPAGE 10% Bis-Tris gels and electroblotted onto polyvinyldifluoride (PVDF) membranes. 
Membranes were treated for 90 min in a blocking buffer containing 5% (w/v) of non-fat 
dehydrated milk to minimize non-specific binding. Total HepG2 cells’ GRP78 expression was 
immunodetected with a 1:200 dilution of anti-GRP78 N-20 antibodies.  The membrane 
associated immunoreactivity was then detected using a 1:5000 dilution of a horseradish 
peroxidase-conjugated anti-goat secondary antibody and detected using ECL Plus 
chemiluminescence.  The resulting autoradiograph was scanned, quantified with NIH ImageJ and 
expressed as integrated pixel density.  
 
5.7.9 CELL VIABILITY  
Cell viability was determined in 24-well plates with HepG2 cells cultured in serum-free 
basal medium for 24 h and then incubated in the presence or absence of varying concentrations 
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of CTP:siRNA (20 M) for 48 h at 37 o C. The samples were removed with Enzyme Free 
Dissociation Buffer for 3 minutes at 37 C. Samples were pelleted and re-suspended in 
Dulbucco’s PBS (1 mL) and Trypan blue 0.4% stain (100 µL) was added. Samples were 
quantified using a Countess automated cell counter. The resulting data was analyzed with 
GraphPad Prism 4.0 and statistical significance was determined by ANOVA (p< 0.05). 
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CHAPTER 6. CONCLUSION AND CONTRIBUTIONS TO KNOWLEDGE  
 
6.1 CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE MADE IN THIS 
THESIS 
 
6.1.1 SYNTHESIS AND CHARACTERIZATION OF BRANCH AND HYPERBRANCH 
siRNAs  
The solid phase synthesis and characterization of a new brand of siRNAs (Figure 2.9) 
has been disclosed in Chapter 2 of this thesis. The siRNA sequences were derived from multiple 
sites of GRP78 mRNA, an oncogene known to trigger cancer proliferation and resistance in a 
wide range of tumors. Therefore, potent silencing of GRP78 mRNA has been shown to 
compromise cancer cell activity leading to the development of potent anti-cancer approaches. 
Towards this unified goal, novel V-shape, 2.8, Y-branch, 2.9, and  hyperbranch, 2.10-2.11, 
siRNAs were synthesized by an efficient semi-automated solid phase synthesis method, 
producing a library (17) of GRP78-silencing siRNAs for exploring structure-activity 
relationships in cancer. Notably, the synthesis procedure featured the use of either 5’-OLv 2’-or 
3’-OMMT ribouridine phosphoramidite branchpoint nucleotides (Scheme 2.2, 2.16 and 2.24), to 
procure the branch and hyperbranch siRNAs in good yields (17-83%) and purities (≥90%) 
following ion pairing reverse-phase HPLC analysis and purification. The sequence identities of 
the siRNAs were confirmed by molecular weight analyses using ESI-MS (Novatia Inc, Newton 
PA), whereas denaturing and native PAGE were used to respectively confirm siRNA purity and 
hybridization for bio-physical and structural studies.  
The biophysical traits and structural characteristics of the newly formed branch and 
hyperbranch siRNAs were also evaluated for the first time in Chapter 3 of this thesis. Namely, 
CD spectroscopy was used to investigate siRNA secondary structure to ascertain the A-type 
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helix in the newly formed siRNAs. This helical trajectory is a requirement for RISC recognition 
of the siRNA substrates for mRNA silencing activity. Moreover, thermal denaturation 
experiments using UV-Vis spectrophotometry were used to evaluate hybrid thermal stability. 
Interestingly, branch and hyperbranch siRNAs displayed stable hybrid structures (Tm: 68 - >90 
o
C) relative to the linear controls (Tm: 67 - 76 
o
C), and in some cases were found to contain 
multiple hybrid-to-single-strand transitions due to the multiple siRNA motifs embedded within 
these types of higher-ordered structures. From these spectroscopic studies, branch and 
hyperbranch siRNAs were found to display the pre-requisite hybrid structures for stimulating 
RNAi activity in cancer.  
 
6.1.2 GRP78 SILENCING AND CELL DEATH ACTIVITY OF BRANCH AND 
HYPERBRANCH siRNAs IN HepG2 CANCER CELLS 
In this study, the RNAi activity of the GRP78-silencing branch and hyperbranch siRNAs 
(Table 2.1, sequence no. 4-7) has been validated for the first time in HepG2 hepatoblastomas. 
HepG2 cells have been shown to overexpress and cell surface localize GRP78, thereby forming a 
valid tumor cell line model for validating the proposed GRP78-silencing strategy and a clinically 
relevant form of pediatric liver cancer for exploring new and improved forms of therapy. In 
chapter 4, the novel V-shape, Y-branch, and  hyperbranch siRNA motifs (Table 2.1, sequence 
no. 4-7) were found to trigger potent GRP78 silencing (50% – 60%) while eliciting noticeable 
apoptosis (~5 - 15%) in HepG2 cells. Significantly, hyperbranch siRNA, 7, targeting GRP78 
mRNA expression at distinct sites was found to trigger more potent GRP78 silencing (60% vs. 
40%) and HepG2 cell death (15% vs. 5%) activity relative to the linear siRNAs, 1 and 2, 
highlighting its synergistic effects. This finding is important for the development of new siRNA 
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constructs that may target multiple genes in a combination approach for improving the RNAi 
effect. Moreover, confocal laser scanning microscopy also supported the western blot data, by 
illustrating significant cell surface GRP78 silencing (~70%) with hyperbranch siRNA, 7. 
Interestingly, FITC-labeling of cell surface GRP78 on HepG2 cells also suggests the possibility 
of developing tumor-targeting strategies (Chapter 5).  
 In Chapter 5, the first steps towards the development of a cancer-targeting gene therapy 
approach are highlighted, by the combination of GRP78-targeting siRNAs and peptides (i.e. 
cancer-targeting peptides, CTPs). In this approach, GRP78-silencing siRNAs are combined with 
poly(arginine) derived CTPs for the selective delivery of siRNAs into GRP78 HepG2 cells for 
RNAi and cell death activity. The CTP:siRNA complexes were effectively characterized by 
native PAGE, CD spectroscopy, thermal denaturation, DLS and TEM experiments. Moreover, 
the transfection of GRP78 silencing siRNA (Table 2.1, sequence no. 1) with a CTP derived 
from the Pep42-R9 sequence demonstrated significant GRP78 silencing (50-60%) and modest 
cell death (5-15%) in HepG2 cells which were in agreement with the Lipofectamine:siRNA 
transfection studies (Chapter 4). These results highlights the utility of the Pep42-R9 sequence as 
a useful transfection reagent that may be applicable in a wide range of tumors that display the 
cell surface GRP78 antigen. This discovery is also important for the development of an effective 
cancer-targeting gene therapy approach, which aims to kill cancer cells selectively, while leaving 
the healthy ones unmarked. 
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APPENDIX B. Supplemental IP RP HPLC Chromatograms and MS spectra 
 
Figure A9. IP RP LC/MS Analysis of (Table 2.1, sequence 1a)   
 
 
Sequence 1a. 
 
  5′-A GUG UUG GAA GAU UCU GAU-3′ 
 
MS.  Calc. 6103.7 g/mol   Found 6103.7 g/mol 
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Figure A10. IP RP LC/MS Analysis of (Table 2.1, sequence 1b)   
 
 
 
Sequence 1b.   
 
5′- A UCA GAA UCU UCC AAC ACU -3′ 
 
MS.  Calc. 5947.4 g/mol   Found 5949.4 g/mol 
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Figure A11. IP RP LC/MS Analysis of (Table 2.1, sequence 2a)   
 
 
 
Sequence 2a. 
 
             5′-G GAG CGC AUU GAU ACU AGA-3′ 
 
MS.  Calc. 6124.5 g/mol   Found 6124.7 g/mol 
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Figure A12. IP RP LC/MS Analysis of (Table 2.1, sequence 2b)   
 
 
 
Sequence 2b. 
 
  5′-UCU AGU AUC AAU GCG CUC C-3′ 
 
MS.  Calc. 5955.3 g/mol   Found 5958.6 g/mol 
 
 
 
 
 
 
 
 
 
 
 
A11 
Figure A13. IP RP LC/MS Analysis of (Table 2.1, sequence 4).   
 
 
Sequence 4. 
 
                        2’3’ UCA CAA CCU UCU AAG ACU A-5’                                    
                  5’-rU                                                                                
             3’5’ AGU GUU GGA AGA UUG UGA U-3’  
 
MS.  Calc. 12412.5 g/mol  Found 12420.5 g/mol 
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Figure A14. IP RP LC/MS Analysis of (Table 2.1, sequence 5).   
 
 
Sequence 5. 
                                                      2’3’ UCA CAA CCU UCU AAG ACU A-5’                   
         5’– UCA CAA CC – 3’5’-rU 
                                                      3’5’ AGU GUU GGA AGA UUG UGA U-3’  
 
MS.  Calc. 14936.0 g/mol  Found 14934.9 g/mol 
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Figure A15. IP RP LC/MS Analysis of (Table 2.1, sequence 6).   
 
 
Sequence 6. 
 
3’-U AGU CUU AGA GGA UUG UGA-5’2’                                           2’3’ UCA CAA CCU UCU AAG ACU A-5’            
                                                                 rU3’5’–UCA CAA CC – 3’5’-rU   
5’-A UCA GAA UCU CCU AAC ACU-3’5’                                            3’5’ AGU GUU GGA AGA UUG UGA U-3’  
 
MS.  Calc. 27419.5 g/mol   Found 27450.0 g/mol 
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Figure A16. IP RP LC/MS Analysis of (Table 2.1, sequence 8).   
 
 
Sequence 8. 
           2’5’ AGU GUU GGA AGA UUG UGA U-3’   
                5’-rU                                                                       
                      3’3’ UCA CAA CCU UCU AAG ACU A-5’  
 
MS.  Calc. 12420.5 g/mol  Found 12428.0 g/mol 
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Figure A17. IP RP LC/MS Analysis of (Table 2.1, sequence 9).   
 
 
Sequence 9. 
                     2’5’ AGU GUU GGA AGA UUG UGA U-3’       
               5’– UCA CAA CC – 3’5’-rU                                            
                                     3’3’ UCA CAA CCU UCU AAG ACU A-5’  
 
MS.  Calc. 14934.9 g/mol   Found  14941.6 g/mol 
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Figure A18. IP RP LC/MS Analysis of (Table 2.1, sequence 10)  
 
 
Sequence 10. 
 
         5’-A UCA GAA UCU CCU AAC ACU-3’3’                                              2’5’ AGU GUU GGA AGA UUG UGA U-3’                  
                                                                              rU2’5’– UCA CAA CC – 3’5’-rU            
            3’-U AGU CUU AGA GGA UUG UGA-5‘5’                                            3’3’ UCA CAA CCU UCU AAG ACU A-5’  
 
MS.  Calc. 27419.5 g/mol   Found 27668.8 g/mol 
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Figure A19. IP RP LC/MS Analysis of (Table 2.1, sequence 11)   
 
 
Sequence 11. 
 
           5’-U CUA GUA UCA AUG CGC UCC-3’3’                                              2’5’ AGU GUU GGA AGA UUG UGA U-3’                  
                                                                               rU2’5’– UCA CAA CC – 3’5’-rU                                           
            3’-A GAU CAU AGU UAC GCG AGG-5‘5’                                              3’3’ UCA CAA CCU UCU AAG ACU A-5’  
 
MS.  Calc. 27449.5 g/mol  Found 27485.2 g/mol 
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Figure A20. IP RP LC/MS Analysis of (Table 2.1, sequence 12a)   
 
 
 
Sequence 12a. 
 
  5′- A UCA GAA UCU UCC AAC ACU -3′ 
 
MS.  Calc. 6075.0 g/mol   Found 6076.0 g/mol 
 
 
Note: Underlined residues refers to 2’-OMe RNA 
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Figure A21. IP RP LC/MS Analysis of (Table 2.1, sequence 12b)   
 
 
Sequence 12b. 
  
 5′-A GUG UUG GAA GAU UCU GAU-3′ 
 
MS.  Calc. 6214.9 g/mol   Found 6215.9 g/mol 
 
Note: Underlined residues refers to 2’-OMe RNA 
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Figure A22. IP RP LC/MS Analysis of (Table 2.1, sequence 14)   
 
 
Sequence 14. 
 
          2’3’ UCA CAA CCU UCU AAG ACU A-5’ 
              5’-rU             
                     3’5′-A GUG UUG GAA GAU UCU GAU-3′  
  
MS.  Calc. 12658.8 g/mol   Found 12659.9 g/mol 
 
Note: Underlined residues refers to 2’-OMe RNA 
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Figure A23. IP RP LC/MS Analysis of (Table 2.1, sequence 15)   
 
 
Sequence 15. 
 
                         2’3’ UCA CAA CCU UCU AAG ACU A-5’  
5’– UCA CAA CC – 3’5’-rU                           
                                  3’5′-A GUG UUG GAA GAU UCU GAU-3′ 
 
MS.  Calc. 15229.5 g/mol   Found 15230.5 g/mol 
 
Note: Underlined residues refers to 2’-OMe RNA 
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Figure A24. IP RP LC/MS Analysis of (Table 2.1, sequence 16)   
 
 
Sequence 16.  
 
         3’-U AGU CUU AGA GGA UUG UGA-5’2’                                             2’3’-UCA CAA CCU UCU AAG ACU -5’            
                                                                              rU3’5’– UCA CAA CC – 3’5’-rU                               
          5’- A UCA GAA UCU UCC AAC ACU-3’5’                                             3’5′-A GUG UUG GAA GAU UCU GAU-3′  
 
MS.  Calc. 27840.2 g/mol   Found 28141.9 g/mol 
  
Note: Underlined residues refers to 2’-OMe RNA 
 
Figure A25. IP RP LC/MS Analysis of (Table 2.1, sequence 17)   
 
 
A23 
 
Sequence 17. 
  
         3’-A GAU CAU AGU UAC GCG AGG -5’2’                                            2’3’-UCA CAA CCU UCU AAG ACU -5’            
                                                                              rU3’5’– UCA CAA CC – 3’5’-rU                                 
          5′-U CUA GUA UCA AUG CGC UCC-3’5’                                              3’5′-A GUG UUG GAA GAU UCU GAU-3′  
 
MS.  Calc. 27870.2 g/mol   Found 27766.3 g/mol 
 
Note: Underlined residues refers to 2’-OMe RNA 
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APPENDIX C. CTP:siRNA PAGE  
 
 
Figure A26. Native gel analysis of Pep42-R9 and (A)Table 2.1 sequence 2; (B) Table 2.1 
sequence 5 and  (C) Table 2.1 sequence 7.  
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APPENDIX D. CTP:siRNA analysis by CD Spectroscopy 
 
Figure A27. CTP:siRNA analysis by CD Spectroscopy.  (A) Table 2.1 Sequence 2, (B) Table 
2.1 Sequence 5, (C) Table 2.1 Sequence 7. 
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APPENDIX E: DLS studies of CTP:siRNA 
 
Table A1. Summary table showing CTP:siRNA studies by DLS and TEM 
 
Sample  
Effective Diameter from DLS 
(nm) Comments 
      
Sequence 2 (Duplex 
siRNA)  ~ 20 monomers  
   600-1000 mostly aggregates 
   Pep42-r9: seq. 2 (50:1)  210 ± 14  Bimodal complex 
  1400 ± 80   
      
Sequence 5 (Y siRNA)  20 ± 5 monomers 
 
 700 -2000 aggregates 
 
  
 Pep42-r9: seq. 5 (50:1) 900 ± 50  Bimodal complex 
 
170 ± 9   
 
    
Sequence 7 
(Hyperbranch siRNA) ~ 20 monomers  
 
 20-2000  mostly aggregates  
   Pep42-r9: seq. 7 (50:1) 340 ± 2   
 
    
 
 
CTP:siRNA (Pep42-R9:siRNA, Sequence no. 2) 
The DLS and TEM both show complex formation with approximately similar sizes around 1000 
nm. However sequence 2 alone is highly aggregated with unstable DLS readings and high 
aggregation seen on TEM grids. This supports the conclusion that complexes are formed because 
the complex duplex is uniform and looks different on TEM grids.  
 
CTP:siRNA (Pep42-R9:siRNA, Sequence no. 5) 
The TEM and DLS results show the population of 170 nm as well as 900 nm population on DLS. 
Complex formation is supported by the observation of uniform complexes seen on grids which 
are not seen in the controls. Sequence 5 alone has a DLS population 5 nm, while on TEM 
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uniform particles of approx. 20-25 nm were observed. In both cases the sequence 5 sizes alone 
are smaller than the sizes seen in complexed samples. 
 
CTP:siRNA (Pep42-R9:siRNA, Sequence no. 7) 
About 340 nm complex size is observed in both  DLS and TEM (300 – 500nm) . Also seen are 
smaller sized particles (approx. 100-300 nm) which could be smaller complexes. Sequence 7 
alone is multimodal with different populations and high aggregation suggested by DLS and 
TEM. The monomeric form is approximately 25 nm, some particles of size 100 nm are seen and 
a few aggregates ranging from 700 -2000 nm are seen.  
 
In all three cases there seems to be complex formation, as deduced from TEM images. DLS data 
does not always correlate with the TEM sizes especially as seen in the siRNA sequences alone, 
mostly due instability or multimodal populations showing aggregation. Sample preparation for 
TEM could also be a contributing factor to slight changes observed when comparing DLS and 
TEM. 
 
APPENDIX F. TEM images of CTP:siRNA 
 
Figure A28. TEM images of Pep42-R9 and (A) Table 2.1 sequence 2; (B) Table 2.1 sequence 
5 and  (C) Table 2.1 sequence 7.  Data explanation provided in Appendix E. 
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APPENDIX G. Thermal melts of CTP: siRNA 
 
Figure A29. Thermal melts of CTP:siRNA between Pep42-R9 and (A) Table 2.1 sequence 2, 
(B) Table 2.1 sequence 5 and  (C) Table 2.1 sequence 7.   
 
 
 
 
